KÖZLEMÉNYJEGYZÉK (Szabó Attila)

KÖZLEMÉNYJEGYZÉK (Szabó Attila) A PhD értekezést követően megjelent közlemények A disszertáció témájában a PhD értekezést követően megjelent első- vagy utolsószerzős közlemények

1. Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Philipp T, Heemann U. Effect of angiotensin-

converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000, 57; 982-991 IF: 4,371 Független idézettség: 48

2. Szabo A, Tulassay T, Melegh B, Szabo T, Vannay A, Fekete A, Süveges Zs, Reusz GS.

Hyperhomocysteinemia and MTHFR C677T gene polymorphism in renal transplant patients. Arch Dis Child 2001; 85: 47-49 IF:2,129 Független idézettség: 8

3. Viklicky O, Hubacek JA, Vitko S, Heemann UW, Vasarhelyi B, Lacha J, Kohnle M, Szabo A. Gprotein β3-subunit and eNOS gene polymorphism and long-term renal graft function. Kidney Blood Press R 2002; 25(4): 245-249I IF: 0.968 Független idézettség: 2

4. Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo AJ. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. Kidney Int 2002; 62 (4): 1364-1371 IF: 5,016 Független idézettség: 11

5. Szabó Attila, Müller Veronika. A transzplantált vese hosszú távú működését befolyásoló faktorok. Orvosi Hetilap 2002, 143(51): 2811-2819

Független idézettség: 2

6. Szabo AJ, L Wagner A Erdely K, Lau C, Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003, 64(5): 1765-1771 IF: 5,302 Független idézettség: 1

7. Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo AJ. Sex differences in the alterations of Na+/K+-ATPase following ischemia/reperfusion injury in the rat kidney. J Physiol (London.) 2004; 555(2): 471-80 IF: 4,346 Független idézettség: 9

8. Müller V, Szabó A. Nemi különbségek a vesebetegségek progressziójában. Lege Artis Medicinae 2004; 14(1): 26-31


9. Vannay A, Fekete A, Müller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo AJ. The effects of histamine and the H2 receptor antagonist ranitidine on ischemia induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor. Kidney Blood Press R 2004; 27: 105-113 IF: 1,067 Független idézettség: 2

10. Fekete A, Viklicky O, Hubácek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between Heat Shock Protein (HSP) 70s and Toll like Receptor Polymorphisms with Long-Term Renal Allograft Survival. Transplant Int 2006; 19: 190–196 IF: 1,797

11. Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in

heat shock protein 72 expression and localization in rats following renal ischaemia-reperfusion injury. Am J Physiol Renal Physiol. 2006; 291(4): F806-F811 IF: 4,263 Független idézettség: 1

Össz IF: 29,259 Független idézettség: 85

A disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények

12. Heemann U, Szabo A, Hamar P, Müller V, Witzke O, Philipp Th. LPS pretreatment protects from renal ischemia/reperfusion injury. Possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000; 156: 287-293 IF: 6,971 Független idézettség: 31

13. Viklicky O, Zou H, Müller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502 IF: 4,035 Független idézettség: 37

14. Hamar P, Liu S, Viklicky O, Szabo A, Müller V, Heemann U. Cyclosporine A and Azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 2000; 69: 1290-1295 IF: 4,035 Független idézettség: 3

15. Losonczy G, Kriston T, Szabo A, Müller V, Harvey J, Hamar P, Heemann U, Baylis C. Male gender predisposes to development of endotoxic shock in the rat. Cardiovasc Res 2000; 47: 183-191 IF: 3,783 Független idézettség: 18

16. Reusz GS Szabo A, Ferenc P, Kenesei É, Sallay P, Latta K, Szabó A, Szabó A. Bone metabolism and mineral density following renal transplantation. Arch Dis Child 2000; 83: 146-151 IF: 1,866 Független idézettség: 19

17. Müller Veronika, Szabó Attila, Becker Gerold, Delfs Michael, Veres Tibor, Albrecht Karl-Heinz, Philipp Thomas, Heemann Uwe. Húgyúti fertőzések hatása a transzplantált vese chronicus kilökődésére. Hypertonia és Nephrologia 2000; 4(3): 141-145

18. Viklicky O, Muller V, Zou H, Szabo A, Vitko S, Heemann U. RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection. Transplant P 2001; 33(3): 2320-2321 IF:0,568 Független idézettség: 2

19. Hamar P, Szabo A, Muller V, Heemann U. The involvement of activated T-cells and growth-factor production in the early and late phase of chronic kidney allograft nephropathy in rats. Transpl Int 2002; 15(9-10): 446-454 IF: 2,520 Független idézettség: 5

20. Losonczy Gy,, Kriston T, Szabó A, Müller V, Harvey J, Heemann U, Baylis C. Nemi különbségek a kísérletes endotoxin sokk kialakulásában. A nitrogén-monoxid szintézis jelentősége. Medicina Thoracalis 2002; 55: 66-73

21. Erdely A, Wagner L, Müller V, Szabo A, Baylis C. Protection of Wistar Furth rat from renal disease is associated with maintained renal nitric oxide. J Am Soc Nephrol 2003; 14(10):2526-33 IF: 7,499 Független idézettség: 7

22. Rajnoch J, Lodererova A, Szabo A, Honsova E, Vannay A, Bloudickova S, Matl I, Viklicky O. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: Effect of tacrolimus. Transplant P 2005; 37(1): 352-354 IF: 0,799 Független idézettség: 1

23. Tain YL, Muller V, Szabo A, Dikalova A, Griendling K, Baylis C. Lack of Long-Term Protective Effect of Antioxidant/Anti-Inflammatory Therapy in Transplant-Induced Ischemia/Reperfusion Injury. Am J Nephrol. 2006; 26(3): 213-217 IF: 2,459

24. Reusz György, Szabó Attila, Remport Ádám, Szabó József, Járay Jenő. Veseátültetés gyermekkorban. Gyermekgyógyászati szemle 2006; 11(3-4): 99-108 Össz impakt faktor: 34,535 Független idézettség: 123

Nem a disszertáció témájában a PhD értekezést követően megjelent első- vagy utolsószerzős közlemények

25. Molnar Z, Farkas V, Nemes L, Reusz GS, Szabo AJ. Hyponatraemic seizures resulting from inadequate post-operative fluid intake following a single dose of desmopressin. Nephrol Dial Transpl 2005; 20: 2265-2267 IF: 2,976 Független idézettség: 1 Össz impakt faktor: 2,840 Független idézettség: 1

Nem a disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények

26. Miltényi G, Tory K, Stubnya G, Sallay P, Dobos M, Vásárhelyi B, Szabo A, Reusz G. Monitoring cardiovascular changes during hemodialysis in children. Pediatr Nephrol 2001; 16: 19-2 IF:1,391 Független idézettség: 1

27. Tory K, Tóth-Heyn P, Szabo A, Stubnya G, Reusz GS. Signs of autonomic neuropathy in childhood uremia. Pediatr Nephrol 2001; 16: 25-28 IF: 1,391


28. Hamar P, Peti-Peterdi J, Szabo A, Becker G, Flach R, Rosivall L, Heemann U. Interleukin-2-dependent mechanism are involved in the development of glomerulosclerosis after partial renal ablation in rats. Exp Nephrol 2001; 9(2): 133-141 IF:1,881 Független idézettség: 5

29. Tory K, Horváth E, Süveges Z, Fekete A, Sallay P, Berta K, Szabó T, Szabo AJ, Tulassay T, Reusz GS. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a doubleblind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol 2004; 61(5): 316-323 IF: 1,316

30. Reusz György, Szabó Attila, Fekete Andrea. Idiopathiás nephrosis szindróma gyermekkorban. Orvosi Hetilap 2006; 147(47): 2251-2260

31. Karoly E, Fekete A, Banki NF, Szebeni B, Vannay A, Szabo AJ, Tulassay T, Reusz GS. Heat Shock Protein 72 (HSPA1B) Gene Polymorphism and Toll-Like Receptor (TRL) 4 Mutation are Associated with Increased Risk of Urinary Tract Infection in Children. Ped Res 2007 (közlésre elfogadva) IF: 2,875 Össz impakt faktor: 8,854 Független idézettség: 9

A PhD értekezést megelőzően megjelent közlemények A disszertáció témájában a PhD értekezést megelőzően megjelent első- vagy utolsószerzős közlemények

32. Szabo A, Viazov S, Heemann U., Kribben A., Philipp Th., Roggendorf M. GBV-C/HGV infection in renal dialysis and transplant patients. Nephrol Dial Transpl 1997; 12: 2380-2384 IF: 1,682 Független idézettség: 17

33. Szabo A, Sallay P, Kribben A, Ross S, Philipp Th, Roggendorf M., Tulassay T., Heemann U. Hepatitis G virus infection in children on dialysis and after renal transplantation. Pediatr Nephrol 1998; 12: 93-95 IF: 1,158 Független idézettség: 3

34. Szabo A, Heemann U. Ischemia/reperfusion and chronic allograft rejection. Transplant P 1998; 30: 4281-4284 IF: 0,740


35. Szabo A, Patschan O, Kuttler B., Müller V., Philipp Th, Rettig R., Heemann U. Hypertension accelerates the pace of chronic allograft rejection in rat. Transplant Int 1998; S11: 10-14 IF: 1,870


36. Szabó A, Heemann U, Müller V, Reusz Gy, Sallay P, Viazov S, Tulassay T. Hepatitis G vírus infekció vesetranszplantált és dializált gyermek és felnőtt betegekben. Orvosi Hetilap 1999; 140(29): 1619-1623 Független idézettség: 4

37. Szabó A, Müller V, Patschan O, Kuttler B, Rettig R, Reusz G, Heemann U. Hypertónia hatása a transzplantált vese krónikus kilökődésére. Hypertonia és Nephrologia 1999; 3(3): 127-131

Össz impakt faktor: 5,450 Független idézettség: 52

A disszertáció témájában a PhD értekezést megelőzően megjelent társszerzős közlemények

38. Müller V, Hamar P, Szabo A, Knust E, Vogelsang M, Heemann U. Effect of mycophenolate mofetil on the in-vivo infiltration of lymphocytes in the rat remnant kidney. Transplant P 1998, 30: 982 IF: 0,740 Független idézettség: 11

39. Witzke O, Becker G, Erhard J, Lütkes P, Szabo A, Philipp Th, Heemann U. Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation. Clin Nephrol 1998, 49: 2427 IF: 1,323 Független idézettség: 3

40. Müller V, Hamar P, Vogelsang M, Szabó A, Philipp T, Heemann U. In-vivo migration of lymphocytes in chronically rejecting rat kidney allografts: essential role of CD18. Transplant Int 1999; 12: 145-151 IF: 1,599 Független idézettség: 2

41. Müller V, Szabó A, Viklicky O, Portl S, Heemann U. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55: 2011-2020 IF: 3,807 Független idézettség: 27

42. Hamar P, Szabó A, Kovács G, Kökény G, Heemann U, Rosiwall L. Az interleukin-2 által közvetített

mechanizmusok szerepet játszanak transplantált patkányvese chronicus kilökődésében. Hypertonia és Nephrologia 1999; 3(2): 102-109

43. Hamar P, Szabo A, Muller V, Heemann U. Involvement of interleukin-2 and growth factors in chronic kidney allograft rejection in rats. Transplant P 2001; 33: 2160-2162 IF: 0,568



Nem a disszertáció témájában a PhD értekezést megelőzően megjelent társszerzős közlemények

44. Ross RS, Viazov S, Schmitt U, Schmolke S, Tacke M, Ofenloch-Haehnle B, Holtman M, Müller N, Da Villa G, Yoshida CF, Oliveira JM, Szabo A, Paladi N, Kruppebacher JP, Philipp Th, Roggendorf M. Distinct prevalence of antibodies to the E2 protein of GB virus C/hepatitis G virus in different parts of the world. J Med Virol 1998; 54: 103-106 IF: 2,594 Független idézettség: 36

45. Reusz György, Sallay Péter, Dobos Mariann, Szabó András, Szabó Attila, Szabó Antal, Tulassay Tivadar. Az oxalátürítés és a vizelet kalcium-oxalát telítettsége izolált haematuriában valamint idiopathiás hypercalciuriában. Gyermekgyógyászat 1998; 6: 560-567

46. Szabó A, Kenesei É, Szabó A, Arató A, Reusz Gy, Tulassay T. Bone turnover index in children and their changes in renal diseases. Klin Kisérl Lab Med = Clin Exp Lab Med 2000; 27: 66-71 (angol nyelvű) Össz impakt faktor: 2,594 Független idézettség: 36

Impakt faktor összesítés és százalékos arány a küszöbértékhez viszonyítva Az első- vagy utolsószerzős publikációk impakt faktora: 37,549 (75,098%) Az első- vagy utolsószerzős publikációk független idézettsége: 138 (69%) A PhD Disszertációt követően és megelőzően publikált első- vagy utolsószerzős közlemények impakt faktorának aránya: 32,099/5,450 (85,48%/14,52%) A PhD Disszertációt követően és megelőzően publikált első- vagy utolsószerzős közlemények független idézettségének aránya: 86/52 (62,3%/37,7%) A PhD Disszertációt követően és megelőzően publikált összes közlemény impakt faktorának aránya: 75,488/16,081 (82,44%/17,56%) Összes impakt faktor: 91,569 Független idézettség: 350 Összes idézettség: 422

Könyvfejezetek: 1. Szabó Attila: Hypertonia és érrendszer. In: Reusz György, Tulassay Tivadar, Fekete Farkas Pál. (szerk.): Hypertonia a gyermekkorban. Golden Book Kiadó, Budapest, 2002 2. Szabó Attila: Tubuláris megbetegedések. XXXII fejezet 1727-1741. In: Oláh Éva (szerk.): Gyermekgyógyászati kézikönyv. Medicina Könyvkiadó Rt., Budapest, 2004 3. Szabó Attila: Befolyásolják-e a nem és a nemi hormonok az átültetett vese működését? 48-50. In: Karátson Dávid, Tordai Attila, Nagy Mariann (szerk.): A Magyary Zoltán Posztdoktori Ösztöndíj. Gondolat Kiadó, Budapest, 2004 4. Tóth-Heyn Péter, Szabó Attila: A gyermekkori vesebetegségek farmakológiája. 13. fejezet 305-336. In: Fekete Ferenc, Gyurkovits Kálmán (szerk.): Gyermekgyógyászati farmakoterápia. B+V Lap- és Könyvkiadó Kft. 2006

Folyóiratban megjelent idézhető előadás absztraktok: 1. Heemann U, Szabó A, Schleimer K, Müller V, Philipp T. Enalapril verlangsamt die chronische Abstossung im Rattenmodell. Nieren Hochdruck 1997, 26: 493 2. Heemann U, Hamar P, Szabó A, Müller V, Witzke O, Schade U, Philipp Th. IL-2 dependent mechanisms are involved in chronic kidney allograft rejection in rats. J Am Soc Nephrol 1997, 8: 657 3. Lütkes P, Witzke O, Erhard J, Szabó A, Philipp Th, Heemann UW. Long-term tacrolimus rescue therapy is useful in kidney transplant recipients remaining on dialysis after steroid resistant acute rejection. Nephrol Dial Transplant 1997, 12: 203 4. Müller V, Hamar P, Szabó A, Vogelsang M, Philipp Th, Heemann U. In-vivo migration of lymphocytes in rejecting rat kidney allografts: essential role of CD18. Nephrol Dial Transpl 1997, 12: 197 5. Rubbert-Lauterbach F, Szabó A, Boehm W, Feldhoff C, Roggendorf M, Sallay P, Bonzel KE, Ballauff A. Vorkommen von Hepatitis-G-Virus (HGV) bei Kindern mit regelmässiger Hämo- und Peritonealdyalisebehandlungen und nach Nierentransplantation. Monatsschr Kinderheilk 1997, 145: 555 6. Rubbert-Lauterbach F, Szabó A, Boehm W, Feldhoff C, Roggendorf M, Sallay P, Ballauff A, Bonzel KE. Prevalence of hepatitis G-virus in children on regular dialysis (HD and PD) treatment and after renal transplantation (TP). Pediatr Nephrol 1997, 11: 75 7. Szabó A, Rubbert-Lauterbach F, Boehm W, Roggendorf M, Sallay P, Ballauff A, Bonzel KE. Vorkommen von Hepatitis-G-Virus (HGV) bei Kindern mit regelmässiger Hämo- und Peritonealdialysebehandlung. Monatsschr Kinderheilk 1997, 145: 215 8. Szabó A, Sallay P, Kribben A, Müller V, Roggendorf M, Tulassay T, Heemann U. Hepatitis G virus infection in children on dialysis and after renal transplantation. Nephrol Dial Transplant, 1997, 12: 114 9. Toronyi É, Járay J, Remport A, Gáti Z, Szabó A, Heemann U. Incidence of hepatitis G virus in kidney transplanted patients. Nephrol Dial Transplant 1997, 9: 229 10. Hamar P, Viklicky O, Szabó A, Müller V, Rosivall L, Heemann U. Cyclosporine A and azathioprine are equipotent in chronic kidney allograft rejection. J Am Soc Nephrol 1998, 9: 651A 11. Hamar P, Peti_peterdi J, Szabó A, Rosivall L, Heemann U. IL-2 dependent mechanisms in the development of glomerulosclerosis after ¾ renal ablation in rats. J Am Soc Nephrol 1998, 9: 89A 12. Heemann U, Szabó A, Müller V, Hamar P, Kribben A, Philipp Th. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection in the rat. J Am Soc Nephrol 1998, 9: 678A

13. Heemann U, Müller V, Szabó A, Viklicky O, Portl S, Kribben A, Philipp Th. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. J Am Soc Nephrol 1998, 9: 678A 14. Müller V, Szabó A, Vikliczky O, Zou H, Heemann U. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. Nephrol Dial Transplant 1998, 13: A251 15. Szabó A, Kribben A, Sallay P, Roggendorf M, Philipp Th, Tulassay T, Heemann U. Hepatitis G virus infection in adults and children treated with hemo- or peritoneal dialysis. Periton Dialysis Int 1998, 18: 107 16. Szabó A, Schleimer K, Müller V, Hamar P, Viklicky O, Heemann U. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection. Nephrol Dial Transplant 1998, 13: 251A 17. Szabó A, Schleimer K, Müller V, Hamar P, Reusz G, Viklicky O, Heemann U. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection. Pediatr Nephrol 1998, 12: C98 18. Szabó A, Müller V, Schleimer K, Hamar P, Viklicky O, Heemann U. Enalapril reduces growth factor production in chronic renal allograft rejection in the rat. Pediatr Transplant 1998, 2(Suppl. 1): 81 19. Viklicky O, Zou H, Müller V, Szabó A, Heemann U. SDZ RAD prevents early manifestation of chronic rejection in rat renal allografts. Nephrol Dial Transplant 1998, 13: A255 20. Zou H, Viklicky O, Kohnle M, Müller V, Szabó A, Lutz J, Heemann U. SDZ-RAD verhindert frühe Manifestationen einer chronischen Rejektion beim Nierenallotransplant Modell der Ratte. Z Transplantationsmedizin 1998, Suppl.: 92 21.Heemann U, Viklicky O, Zou H, Müller V, Szabó A, Lacha J. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. J Am Soc Nephrol 1999, 10: 703A-704A 22. Reusz G, Szabó A, Szabó A, Szabó A, Sallay P. Characterization of bone metabolism in chronic pediatric renal diseases. J Am Soc Nephrol 1999, 10: 603A 23. Szabó A, Kenesei É, Arató A, Reusz G, Szabó A. Bone turnover index in children and their changes in renal diseases. Clin Chem Lab Med 1999, 37(Suppl.): S436 24. Szabó A, Müller V, Hamar P, Vogelsang M, Tulassay T, Heemann U. Die in-vivo Migration von Lymphozyten in Nieren die chronisch abgestossen werden, wird hauptsächlich durch CD18 vermittelt. Monatsschr Kinderh 1999, 147: 229 25. Szabó A, Patschan O, Müller V, Reusz G, Rettig R, Heemann U. The role of hypertension in chronic renal allograft dysfunkction. Pediatr Nephrol 1999, 13: C86 26. Reusz G, Szabó A, Kenesei É, Sallay P, Tóth-Heyn P, Thole H, Szabó A, Arató A, Péter F. Bone metabolism and mineral density in transplanted patients. Pediatr Nephrol 2000, 14: C106 27. Reusz G, Szabó A, Sallay P, Szabó A, Kenesei É, Tulassay T. Charakterisierung des Knochenmetabolismus in chronischen Nierenerkrankungen. Monatsschr Kinderh 2000, 148: 195 28. Szabó A, Müller V, Schleimer K, Reusz G, Vogelsang M, Heemann U. Enalapril hemmt die Produktion von Wachstumsfaktoren in der chronischen Abstossung. Monatsschr Kinderh 2000, 148: 207 29. Szabó A, Müller V, Viklicky O, Reusz G, Tulassay T, Heemann U. The influence of sex hormones and gender related differences on chronic renal allograft rejection. Pediatr Nephrol 2000, 14: C109 30. Szabo AJ, Tulassay T, Melegh B, Szabo A, Szabo T, Sallay P, Müller V, Reusz GS. Hyperhomozysteinämie und MTHFR-C677T-Genpolymorphismus bei nierentransplantierten Jugendlichen. Nieren und Hochdruckkr 2001, 30/3: 121 31. Fekete A, Müller V, Vannay A, Kocsis I, Heninger E, Vér A, Tulassay T, Szabó AJ. Gender differences during ischemia/reperfusion injury in rat kidney: the role of HSP72 and Na+/K+. Monatsschr Kinderh 2001, 149(Suppl. 2.): S11

32. Fekete A, Melegh B, Szabó T, Müller V, Tulassay T, Reusz GS, Szabó AJ. Hyperhomocysteinemia and polymorphism of the MTHFR gene in renal transplant children. Monatsschr Kinderh 2001, 149 (Suppl. 2.): S17 33. Wagner L, Erdely A, Szabó A, Baylis C. Decreased renal nitric oxide synthase (NOS) activity occurs early in chronic progressive renal disease (CRD). J Am Soc Nephrol 2001, 12: A4335 34. Fekete A, Vannay A, Vér A, Vásárhelyi B, Müller V, Reusz G, Tulassay T, Szabó AJ. Gender differences in renal Na/K ATPase in rats. Pediatr Nephrol 2002, 17: C62 35. Erdely A, Szabo A, Wagner L, Baylis C. Decreased neuronal (n) nitric oxide synthase (NOS) and progressive chronic renal disease (CRD). J Am Soc Nephrol 2002, 13: 344A 36. Fekete A, Vannay A, Vér A, Vásárhelyi B, Müller V, Reusz G, Tulassay T, Szabó AJ. Gender differences in renal Na+/K+ ATPase (NKA) during ischemia/reperfusion injury in rats. J Am Soc Nephrol 2002, 13: 755A 37. Müller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabó AJ. Sexual dimorphism in renal ischemia-reperfusion injury on rats: possible role of endothelin. J Am Soc Nephrol 2002, 13: 756A 38. Müller V, Szabo A, Baylis C. Changes in renal endothelial and neuronal nitric oxide synthase (eNOS, nNOS) protein abundance in chronic allograft rejection in rats. J Am Soc Nephrol 2002, 13: 558A 39. Szabo A, Müller V, Baylis C. Gender difference in endothelial and neuronal nitric oxide synthase (eNOS and nNOS) expression in kidney cortex following low dose Cyclosporine-A (CsA) treatment. J Am Soc Nephrol 2002, 13: 372A 40. Szabo A, Erdely A, Müller V, Baylis C. Strain differences in renal neuronal nitric oxide synthase (nNOS) protein abundance. J Am Soc Nephrol 2002, 13: 737A 41. Szabo A, Müller V, Erdely A, Baylis C. Gender based immunosuppression? Different effects of cyclosporine A (CsA) and rapamycin (Rapa) on renal endothelial and neuronal nitric oxide synthase (eNOS and nNOS) expression. Nephrol Dial Transplant 2003, 18 (Suppl. 4.): 792 42. Müller V, Losonczy G, Heemann U, Fekete A, Vannay A, Reusz G, Tulassay T, Szabo A. The effect of gender and sexual steroids on renal ischemia-reperfusion injury. Nephrol Dial Transplant 2003, 18 (Suppl. 4.): 604 43. Tory K, Suveges Zs, Sallay P, Berta K, Szabo A, Tulassay T, Reusz G. A new parameter designed to differentiate the effect of autonomic neuropathy from that of sympathetic overactivity on heart rate variability in hemodialysis patients. Nephrol Dial Transplant 2003, 18 (Suppl. 4.): 535 44. Szabo AJ, Müller V, Erdely A, Baylis C. Gender based immunosuppression? Pediatr Nephrol 2003, 18: C21 45. Szabó A, Fekete A, Vannay Á, Losonczy Gy, Heemann U, Reusz Gy, Müller V. Nemi különbségek a hemodinamikában a vese ischémia/reperfúziós károsodását követően. Hypertonia és Nephrologia 2003, 7 (S4): 136 46. Fekete A, Viklicky O, Treszl A, Körmendy R, Heemann U, Teplan V, Reusz Gy, Tulassay T, Szabó AJ. Összefüggés a HSP70 és a TOLL-like receptor genetikai polimorfizmusai, valamint a graftok hosszú távú túlélése között vesetranszplantált betegcsoportokban. Hypertonia és Nephrologia 2003, 7 (3-4): 212 47. Kökény G, Regős A, Antus B, Szabó A, Rosival L, Hamar P. A donor vese perfúziója alapvetően meghatározza a korai graftfunkciót vesetranszplantált patkányban. Hypertonia és Nephrologia 2003, 7 (3-4): 215 48. Müller V. Baylis C, Szabó A. Renalis endothelialis és neuronális nitrogén-monoxid-szintáz (eNOS és nNOS) fehérje expresszió krónikus allograft-nephropathiás nőstény patkányokban. Hypertonia és Nephrologia 2003, 7 (3-4): 218

49. Szabó A, Müller V, Erdely A, Baylis C. A kísérletes vesetranszplantációban használt állatmodell nitrogenmonoxid (NO) függő? Hypertonia és Nephrologia 2003, 7 (3-4): 220 50. A Fekete, A Vannay, A Vér, B Vasarhelyi, V Müller, G Reusz, T Tulassay, AJ Szabo. Geschlechtsspezifische Veränderungen der Na+-K+-ATPase nach Ischämie/Reperfusionsschädigung der Rattenniere. Nieren- und Hochdruckkrankheiten 2004, 33/3: 146 51. Szabó A, Molnár Z. Akut vízmérgezés dezmopresszin kezelés után. Medicina Thoracalis 2004-Suppl., 36 52. Müller V, Szabó A, Rusai K, Losonczy Gy, Muraközy G, Magyar P. HSP70 és TLR-4 polimorfizmus vizsgálata krónikus obstruktív tüdőbetegekben. Medicina Thoracalis 2004-Suppl., 49 53. Bloudicková S, Rajnoch J, Skaroupková P, Szabo A, Muller V, Vikliczky O. Role nNOS a pohlavi v ischemicko-reperfuznim poskozeni: klinická a morfologická analyza. Aktuality V Nefrologii 2004-Suppl1., 2829 54. AJ Szabo, V Müller, A Erdely, GS Reusz, C Baylis. Neuronal nitric oxide synthase (nNOS) in chronic allograft nephropathy: Role of immunosuppressions and gender. Ped Nephrol 2004, 19: C132 55. A Fekete, A Vannay, A Ver, B Vasarhelyi, V Müller, N Ouyang, G Reusz, T Tulassay, AJ Szabo. Gender differences in the alterations of Na+/K+-ATPase following ischemia/reperfusion injury in the rat kidney. Ped Nephrol 2004, 19: C77 56. A Szabo, A Fekete, G Reusz, K Rusai, J Rajnoch, V Müller, O Viklicky. Die Rolle des nNOS nach ischämischer/reperfusorischer Beschädigung der Nieren: Geschlechtsunterschiede. Nieren- und Hochdruckkrankheiten 2005, 34/4: 182 57. A Szabo, A Vannay, V Muller, A Ver, K Rusai, G Reusz, A Fekete. Gender differences in the ischemia induced acute renal failure: the role of Na/K ATPase and HSP72. Ped Nephrol 2005, 20(9): C26 58. K Rusai, A Fekete, O Viklicky, V Müller, B Szebeni, G Reusz, T Tulassay, A Szabo. The role of neuronal nitric oxyde synthase (nNOS) inhibition in renal ischemia-reperfusion (IR) injury: gender differences. Ped Nephrol 2005, 20(9): C110 59. Fekete A, Banki F Viklicky O, Hubacek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival. Pediatr Nephrol 2006, 21(10): C76 60. Bánki Nóra, Fekete Andrea, Andrej Viklicky, Uwe Heemann, Müller Veronika, Reusz György, Szabó Attila. HSP70 és a Toll-like receptor 4 polimorfizmusai és a vesetranszplantátum hosszútávú túlélése. Hypertonia és Nephrologia 2006, 10: 12 61. Fekete Andrea, Szabó Attila. Nemi különbségek a renalis ischemia/reperfuziós károsodásban 1. Hypertonia és Nephrologia 2006, 10: 12 62. Szabó Attila, Fekete Andrea. Nemi különbségek a renalis ischemia/reperfuziós károsodásban 2. Hypertonia és Nephrologia 2006, 10: 12

HIVATKOZÁSI JEGYZÉK (Szabó Attila) A PhD értekezést követően megjelent közlemények A disszertáció témájában a PhD értekezést követően megjelent első- vagy utolsószerzős közlemények

47. Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Philipp T, Heemann U. Effect of angiotensinconverting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000, 57; 982-991 IF: 4,371 Független idézettség: 48 1. Eddy A A. Molecular basis of renal fibrosis. PEDIAT NEPHROL, 15: 290-301 (2000) Gilbert R E, Kelly D J, Cox A J, Wilkinson Berka J L, Rumble J R, Osicka T, Panagiotopoulos S, Lee V, Hendrich E C, 2. Jerums G, Cooper M E. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. DIABETOLOGIA, 43: 1360-1367 (2000) Vazquez M A, Jeyarajah D R, Kielar M L, Lu C Y. Long-term outcomes of renal transplantation: a result of the original 3. endowment of the donor kidney and the inflammatory response to both alloantigens and injury. CURR OPIN NEPHROL HYPERTENS, 9: 643-648 (2000) Abdi R, Huong T T B, Zee R, Brenner B M, Milford E L. Angiotensin gene polymorphism as a determinant of 4. posttransplantation renal dysfunction and hypertension. TRANSPLANTATION, 72: 726-729 (2001) Antus B, Exton M S, Rosivall L. Angiotensin II: A regulator of inflammation during renal disease? INT J * 5. IMMUNOPATHOL PHARMACOL, 14: 25-30 (2001) 6. Danovitch G M. Can ACE inhibitors prevent chronic allograft failure? AMER J KIDNEY DIS, 37: 866-869 (2001) Danovitch G M. Reduction of cardiovascular morbidity in kidney transplant recipients. CURRENT OPINION IN 7. ORGAN TRANSPLANTATION, 6: (2) 145-150 (2001) Fellstrom B. Nonimmune risk factors for chronic renal allograft disfunction. TRANSPLANTATION, 71: SS10-SS16 8. (2001) Gilbert R E, Wilkinson Berka J L, Kelly D J. Angiotensin and renal fibrosis. CONTRIB NEPHROL, (135):171-86 9. (2001) Heemann U, Philipp T. Can ACE inhibitors prevent chronic allograft failure? Reply. AMER J KIDNEY DIS, 37: 869* 10. 870 (2001) Olyaei A J, De Mattos A M, Bennett W M. Nephrotoxicity of immunosuppressive drugs: New insight and preventive 11. strategies. CURRENT OPINION IN CRITICAL CARE, 7: (6) 384-389 (2001) Paskalev E. Chronic failure of renal transplant and ace inhibitors. NEPHROLOGY, DIALYSIS AND 12. TRANSPLANTATION, 7: 34-37 (2001) Shibab F S. Renin-angiotensin system in chronic renal allograft dysfunction. CONTRIB NEPHROL, (135):222-34 13. (2001) Smit van Oosten A, Navis G, Stegeman C A, Joles J A, Klok P A, Kuipers F, Tiebosch A T M G, van Goor H. Chronic 14. blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J PATHOL, 194: 122-129 (2001) Womer K L, Lee R S, Madsen J C, Sayegh M H. Tolerance and chronic rejection. PHIL TRANS ROY SOC LONDON B, 15. 356: 727-738 (2001) Di Paolo S, Schena A, Stallone G, Grandaliano G, Soccio M, Cerullo G, Gesualdo L, Schena F P. Captopril enhances transforming growth factor (TGF)-beta(1) expression in peripheral blood mononuclear cells: A mechanism 16. independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. TRANSPLANTATION, 74: 1710-1715 (2002) 17. Fellstrom B. Chronic renal allograft dysfunction. TransplantLinc, 4: (1) 77-83 (2002) Fischereder M, Kruger B, Kramer B K. Chemokine and renal transplantation [Chemokine und nierentransplantation]. 18. TRANSPLANTLINC, 4: (1) 47-57 (2002) Gourishankar S, Melk A, Halloran P. Nonimmune mechanisms of injury in renal transplantation. TRANSPLANTATION 19. REVIEWS, 16: (2) 73-86 (2002) Jugdutt B I, Menon V, Kumar D, Idikio H. Vascular remodeling during healing after myocardial infarction in the dog 20. model - Effects of reperfusion, amlodipine and enalapril. J AMER COLL CARDIOL, 39: 1538-1545 (2002) Lin J, Valeri A M, Markowitz G S, D Agati V D, Cohen D J, Radhakrishnan J. Angiotensin converting enzyme 21. inhibition in chronic allograft nephropathy. TRANSPLANTATION, 73: 783-788 (2002) Richter M H C, Richter H, Barten M, Schramm D, Gummert J, Mohr F W, Skupin M, Olbrich H G. Angiotensin II type 22. 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study. TRANSPLANT PROC, 34: 1484-1485 (2002)

*

*

*

*

*

Sola R, Paredes D, Antonijoan R M, Estorch M, Vila L P, Guirado L L, Diaz J M, Gich I, Barbanoj M J. Glomerular 23. hyperfiltration, intrarenal hemodynamics, and chronic allograft nephropathy: Physiopathology of chronic allograft nephropathy. TRANSPLANT PROC, 34: 340-+ (2002) Song E W, Zou H Q, Yao Y S, Proudfoot A, Antus B, Liu S Y, Jens L, Heemann U. Early application of Met-RANTES 24. ameliorates chronic allograft nephropathy. KIDNEY INT, 61: 676-685 (2002) Takahara S, Moriyama T, Kokado Y, Hanafusa T, Yazawa K, Yi S, Tanaka T, Kojima Y, Tabata T, Oka K, Imai E. 25. Randomized prospective study of effects of benazepril in renal transplantation: An analysis of safety and efficacy. Clinical and Experimental Nephrology, 6: (4) 242-247 (2002) Aldamiz Echevarria L, Sanjurjo P, Vallo A, Aguirre M, Perez Nanclares G, Gimeno P, Rueda M, Ruiz J I, Rodriguez 26. Soriano J. Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants. PEDIAT NEPHROL, 18: 749-755 (2003) Cantarovich F, Rangoonwala B. Therapeutic effects of angiotensin II inhibition or blockade on the progression of 27. chronic renal disease. INT J CLIN PRACT, 57: 801-822 (2003) Fellstrom B. Donor antigen-independent risk factors for chronic allograft nephropathy. TRANSPLANTATION 28. REVIEWS, 17: (2) 61-66 (2003) Gabriels G, August C, Grisk O, Steinmetz M, Kosch M, Rahn K H, Schlatter E. Impact of renal transplantation on small 29. vessel reactivity. TRANSPLANTATION, 75: 689-697 (2003) Ghods A J, Ossareh S. Beneficial effect of enalapril on slowing the progression of chronic renal allograft dysfunction. 30. TRANSPLANT PROC, 35: 2641-2642 (2003) Jeong H J, Kim Y S, Kwon K W, Kim M S, Kim S I, Choi K H, Lee H Y, Han D S, Park K. Segmental glomerulosclerosis 31. in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril. CLIN TRANSPLANT, 17: 108-113 (2003) Kamimura M, Orth S R. Altered tubular albumin degradation in the pathogenesis of albuminuria: additional 32. experimental evidence challenging the paradigm of glomerular capillary leakage. J HYPERTENSION, 21: 269-271 (2003) Lutz J, Zou H Q, Liu S Y, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with 33. everolimus. TRANSPLANTATION, 76: 508-515 (2003) Orth S R, Odoni G, Karkoszka H, Ogata H, Viedt C, Amann K, Ferrari P, Ritz E. Combination treatment with an ETA34. receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. NEPHROL DIALYSIS TRANSPLANT, 18: 62-69 (2003) Powis S H. Halting chronic allograft nephropathy - Do we already have the drugs? NEPHRON CLIN PRACT, 95: 35. C73-C74 (2003) Richter M H C, Richter H R, Olbrich H G, Mohr F W. Two good reasons for an angiotensin-II type 1 receptor blockade 36. with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy. TRANSPLANT INT, 16: 26-32 (2003) Schindler R, Tullius S G, Tanriver Y, Noack K, Qun Y, Jurgensen J S, Frei U. Hypertension increases expression of 37. growth factors and MHC II in chronic allograft nephropathy. KIDNEY INT, 63: 2302-2308 (2003) Smit-van Oosten A, Stegeman C A, van Goor H. RAS blockade in experimental renal transplantation. Benefits and 38. limitations. Current Drug Targets - Cardiovascular and Haematological Disorders, 3: (1) 73-79 (2003) Tylicki L, Habicht A, Watschinger B, Horl W H. Treatment of hypertension in renal transplant recipients. CURR OPIN 39. UROL, 13: 91-98 (2003) Akcay A, Sezer S, Ozdemir F N, Arat Z, Atac F B, Verdi H, Colak T, Haberal M. Association of the genetic 40. polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. TRANSPLANTATION, 78: 892-898 (2004) Cheung C Y. Vascular endothelial growth factor activation of intramembranous absorption: A critical pathway for 41. amniotic fluid volume regulation. J SOC GYNECOL INVESTIGATION, 11: 63-74 (2004) Magee C C, Milford E. Clinical aspects of renal transplantation. In: Brenner B.M. (szerk.) Brenner and reactor's the 42. kidney, Philadelphia: Saunders, 2004. 2805-2848 Montanaro D, Gropuzzo M, Tulissi P, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani G L, Sainz M, Bresadola F, 43. Mioni G. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration. TRANSPLANT PROC, 36: 692-694 (2004) Muller V, Szabo A. Gender associated differences in the progression of renal diseases [Nemi kuu loo nbsegek a 44. vesebetegsegek progressziojaban]. LEGE ARTIS MEDICINAE, 14: (1) 26-31 (2004) Namba Y, Moriyama T, Kyo M, Oka K, Kokado Y, Shi Y, Imamura R, Ichimaru N, Okuyama A, Takahara S. 45. Comparison of histopathological characteristics of allograft biopsy between responder and non-responder to antiproteinuric effect of angiotensin-converting enzyme inhibitor (ACEI). CLIN TRANSPLANT, 18: 29-33 (2004) Philipp S, Pagel I, Hohnel K, Lutz J, Buttgereit J, Langenickel T, Hamet P, Dietz R, Willenbrock R. Regulation of 46. caspase 3 and Fas in pressure overload-induced left ventricular dysfunction. EUR J HEART FAIL, 6: 845-851 (2004) Stallone G, Infante B, Di Paolo S, Schena A, Grandaliano G, Gesualdo L, Schena F P. Sirolimus and angiotensin47. converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. NEPHROL DIALYSIS TRANSPLANT, 19: 2906-2908 (2004) Wang M H, Liu S Y, Ouyang N, Song E W, Lutz J, Heemann U. Protective effects of FTY720 on chronic allograft 48. nephropathy by reducing late lymphocytic infiltration. KIDNEY INT, 66: 1248-1256 (2004)

49. 50. * 51. 52.

53.

54. 55. * 56. 57.

Zaltzman J S, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. NEPHROL DIALYSIS TRANSPLANT, 19: 940-944 (2004) Fellstrom B, Holdaas H, Jardine A G, Nyberg G, Gronhagen Riska C, Madsen S, Neumayer H H, Cole E, Maes B, Ambuhl P, Olsson A G, Staffler B, Pedersen T R. Risk factors for reaching renal Endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial. TRANSPLANTATION, 79: 205-212 (2005) Lutz J, Yao Y S, Song E W, Antus B, Hamar P, Liu S Y, Heemann U. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. TRANSPLANTATION, 79: 655-661 (2005) Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani G L, Sainz M, Bresadola F, Mioni G. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. TRANSPLANT PROC, 37: 991-993 (2005) Reis K, Arinsoy T, Derici U, Gonen S, Bicik Z, Soylemezoglu O, Yasavul U, Hasanoglu E, Sindel S. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. CLIN TRANSPLANT, 19: 10-14 (2005) Berthier C C, Lods N, Joosten S A, van Kooten C, Leppert D, Lindberg R L P, Kappeler A, Raulf F, Sterchi E E, Lottaz D, Marti H P. Differential regulation of metzincins in experimental chronic renal allograft rejection: Potential markers and novel therapeutic targets. KIDNEY INT, 69: 358-368 (2006) Ersoy A. Current and future antihypertensive drugs in post-transplant hypertension and related patents. EXPERT OPIN THER PAT, 16: (8) 1093-1106 (2006) Lutz J, Risch K, Liu S, Antus B, Schmaderer C, Roos M, Ouyang N, Lehmann M, Heemann U. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. KIDNEY INT, 70: (6) 1080-1088 (2006) Ishizaka N, Matsuzaki G, Saito K, Noiri E, Mori I, Nagai R. Expression and localization of PDGF-B, PDGF-D, and PDGF receptor in the kidney of angiotensin II-infused rat. LABORATORY INVESTIGATION 86 (12): 1285-1292 (2006)

48. Szabo A, Tulassay T, Melegh B, Szabo T, Vannay A, Fekete A, Süveges Zs, Reusz GS. Hyperhomocysteinemia and MTHFR C677T gene polymorphism in renal transplant patients. Arch Dis Child 2001; 85: 47-49 IF:2,129 Független idézettség: 8 1. 2. 3. 4. 5. * 6. 7. 8. 9.

Ueland P M, Monsen A L B. Total homocysteine is making its way into pediatric laboratory diagnostics – Commentary. EUR J CLIN INVEST, 31: 928-930 (2001) Aldamiz Echevarria L, Sanjurjo P, Vallo A, Aquino L, Perez Nanclares G, Gimeno P, Rueda M, Ruiz J I, Urreizti R, Rodriguez Soriano J. Hyperhomocysteinemia in children with renal transplants. PEDIAT NEPHROL, 17: 718-723 (2002) Filler G, Hocher B. The emerging role of gene polymorphisms determining outcome after solid-organ transplantation. PEDIATR TRANSPLANT, 6: 12-14 (2002) Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben Abdallah T, Massy Z A, Ben Maiz H, Lacour B, Mebazaa A. Hyperhomocysteinemia and end-stage renal disease: Determinants and association with cardiovascular disease in Tunisian patients. CLIN CHEM LAB MED, 41: 675-680 (2003) Monsen A L B, Ueland P M. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence. AMER J CLIN NUTR, 78: 7-21 (2003) Tory K, Suveges Z, Horvaath E, Bokor E, Sallay P, Berta K, Szabo A, Tulassay T, Reusz G S. Autonomic dysfunction in uremia assessed by heart rate variability. PEDIAT NEPHROL, 18: 1167-1171 (2003) Ueland P M, Monsen A L B. Hyperhomocysteinemia and B-vitamin deficiencies in infants and children. CLIN CHEM LAB MED, 41: 1418-1426 (2003) Belson A, Sanchez J, Alexander S R, Salvatierra O, Dar M H, Reif S, Yorgin P D. Hyperhomocysteinemia in pediatric and young adult renal transplant recipients. PEDIATR TRANSPLANT, 8: 161-166 (2004) Viklicky O, Hubacek J A, Kvasnicka J, Matl I, Voska L, Skibova J, Teplan V, Vitko S. Association of methylenetetrahydrofolate reductase T677 allele with early development of chronic allograft nephropathy. CLIN BIOCHEM, 37: 919-924 (2004)

49. Viklicky O, Hubacek JA, Vitko S, Heemann UW, Vasarhelyi B, Lacha J, Kohnle M, Szabo A. Gprotein β3-subunit and eNOS gene polymorphism and long-term renal graft function. Kidney Blood Press R 2002; 25(4): 245-249I IF: 0.968 Független idézettség: 2

Cobo M, Barrios Y, Inigo P, Bigo C, Alvarez A, Martin B, Campistol J M, Hernandez D, Salido E, Torres A. Analyses of 1. genetic risk factors associated to chronic nephropathy of renal transplant: genetic polimorphisms of cytokynes, adhesion molecules, platelet-coagulation system and cardiovascular risk markers. NEFROLOGIA, 24: 49-56 (2004) Khan F, Agrawal S, Agrawal S. Genetic predisposition and renal allograft failure - Implication of non-HLA genetic 2. variants. MOLECULAR DIAGNOSIS & THERAPY 10 (4): 205-219 2006

50. Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo AJ. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. Kidney Int 2002; 62 (4): 1364-1371 IF: 5,016 Független idézettség: 11 Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo A J. Sex differences in the * 1. alterations of Na+,K+-ATPase following ischaemia-reperfusion injury in the rat kidney. J PHYSIOL-LONDON, 555: 471-480 (2004) Muller V, Szabo A. Gender associated differences in the progression of renal diseases. LEGE ARTIS MEDICINAE, 14: * 2. (1) 26-31 (2004) Park K M, Kim J I, Ahn Y, Bonventre A J, Bonventre J V. Testosterone is responsible for enhanced susceptibility of 3. males to ischemic renal injury. J BIOL CHEM, 279: 52282-52292 (2004) Shibata Y, Takaoka M, Maekawa D, Kuwahara C, Matsumura Y. Involvement of nitric oxide in the suppressive effect of 4. 17 beta-estradiol on endothelin-1 overproduction in ischemic acute renal failure. J CARDIOVASC PHARMACOL, 44: S459-S461 (2004) Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal * 5. vascular endothelial growth factor mRNA expression and protein level in post-ischaemic rat kidneys. EXP PHYSIOL, 89: 435-444 (2004) Vannay A, Fekete A, Muller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo A J. Effects of histamine and * 6. the H2 receptor antagonist ranitidine on ischemia-induced acute renal failure: Involvement of IL-6 and vascular endothelial growth factor. KIDNEY BLOOD PRESSURE RES, 27: 105-113 (2004) Gu Y L, Dirsch O, Dahmen U, Ji Y, He Q, Chi H D, Broelsch C E. Impact of donor gender on male rat recipients of 7. small-for-size liver grafts. LIVER TRANSPLANT, 11: 669-678 (2005) Kher A, Meldrum K K, Wang M J, Tsai B M, Pitcher J A, Meldrum D R. Cellular and molecular mechanisms of sex 8. differences in renal ischemia-reperfusion injury. CARDIOVASC RES, 67: 594-603 (2005) Park K M, Cho H J, Bonventre J V. Orchiectomy reduces susceptibility to renal ischemic injury: a role for heat shock 9. proteins. BIOCHEM BIOPHYS RES COMMUN, 328: 312-317 (2005) Reckelhoff J F, Yanes L L, Iliescu R, Fortepiani L A, Granger J P. Testosterone supplementation in aging men and 10. women: possible impact on cardiovascular-renal disease. AMER J PHYSIOL-RENAL PHYSIOL, 289: F941-F948 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The * 11. role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Sudo T, Ishii A, Asami J, Uematsu Y, Saitoh M, Nakamura A, Tada N, Ohnuki T, Komurasaki T, Nakagawa J. 12. Transgenic mice over-expressing dicarbonyl/L-xylulose reductase gene crossed with KK-A(y) diabetic model mice: An animal model for the metabolism of renal carbonyl compounds. EXP ANIM, 54: 385-394 (2005) Wei Q Q, Wang M H, Dong Z. Differential gender differences in ischemic and nephrotoxic acute renal failure. AMER J 13. NEPHROL, 25: 491-499 (2005) Choudhry M A, Bland K I, Chaudry I H. Gender and susceptibility to sepsis following trauma. ENDOCR METAB 14. IMMUN DISORD DRUG TARG, 6: (2) 127-135 (2006) Kim J, In S K, Young M S, Eun S Y, Dae K K, Dong G L, Park J -W, Bonventre J V, Kwon M P. Orchiectomy attenuates 15. post-ischemic oxidative stress and ischemia/reperfusion injury in mice: A role for manganese superoxide dismutase. J BIOL CHEM, 281: (29) 20349-20356 (2006) 16. Metcalfe P D, Meldrum K K. Sex differences and the role of sex steroids in renal injury. J UROL, 176: 15-21 (2006) Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock * 17. protein 72 expression and localization in rats following renal ischemia-reperfusion injury. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 291 (4): F806-F811 (2006)

51. Szabó Attila, Müller Veronika. A transzplantált vese hosszú távú működését befolyásoló faktorok. Orvosi Hetilap 2002, 143(51): 2811-2819 Független idézettség: 2 Yang Y L, Li J P, Dou K F, Li K Z. Influence of liver nonparenchymal cell infusion combined with Cyclosporin A on rejection of rat small bowel transplantation. WORLD J GASTROENTERO, 9: (12) 2859-2862 (2003) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role 2. of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. Hypertonia és Nephrologia, 9 (3-4): 150-156 (2005) 1.

52. Szabo AJ, L Wagner A Erdely K, Lau C, Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003, 64(5): 1765-1771 IF: 5,302 Független idézettség: 1

* 1. 2. * 3. * 4. * 5. * 6. * 7.

Erdely A, Freshour G, Smith C, Engels K, Olson J L, Baylis C. Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. AMER J PHYSIOL-RENAL PHYSIOL, 287: F81-F89 (2004) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Baylis C. Acute and long-term effects of modified hemoglobin (HBOC-201) in a rat model of hypertension and chronic kidney disease. TRANSFUSION, 46: 1104-1111 (2006) Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. NAT CLIN PRACT NEPHROL, 2: 209-220 (2006) Baylis C. Nitric oxide deficiency in chronic renal disease. EUR J CLIN PHARMACOL, 62: 123-130 (2006) Erdely A, Freshour G, Baylis C. Resistance to renal damage by chronic nitric oxide synthase inhibition in the WistarFurth rat. AMER J PHYSIOL-REGUL INTEGR C, 290: R66-R72 (2006) Tain YL, Muller V, Szabo A, Dikalova A, Griendling K, Baylis C. Lack of long-term protective effect of antioxidant/anti-inflammatory therapy in transplant-induced ischemia/reperfusion injury. AMERICAN JOURNAL OF NEPHROLOGY 26 (3): 213-217 2006

53. Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo AJ. Sex differences in the alterations of Na+/K+-ATPase following ischemia/reperfusion injury in the rat kidney. J Physiol (London.) 2004; 555(2): 471-80 IF: 4,346 Független idézettség: 9 Narkar V, Kunduzoa O, Hussain T, Cambon C, Parini A, Lokhandwala M. Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney. KIDNEY INT, 66: (2) 633-640 (2004) Caron A, Desrosiers R R, Beliveau R. Ischemia injury alters endothelial cell properties of kidney cortex: Stimulation of 2. MMP-9. EXP CELL RES, 310: 105-116 (2005) Kher A, Meldrum K K, Wang M J, Tsai B M, Pitcher J A, Meldrum D R. Cellular and molecular mechanisms of sex 3. differences in renal ischemia-reperfusion injury. CARDIOVASC RES, 67: 594-603 (2005) Schlattjan J H, Biggemann F, Greven J. Gender differences in renal tubular taurocholate transport. NAUNYN4. SCHMIED ARCH PHARMACOL, 371: 449-456 (2005) Wei Q Q, Wang M H, Dong Z. Differential gender differences in ischemic and nephrotoxic acute renal failure. AMER J 5. NEPHROL, 25: 491-499 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The *6. role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Du X J, Fang L, Kiriazis H. Sex dimorphism in cardiac pathophysiology: Experimental findings, hormonal mechanisms, 7. and molecular mechanisms. PHARMACOL THER, 111: 434-475 (2006) 8. Metcalfe P D, Meldrum K K. Sex differences and the role of sex steroids in renal injury. J UROL, 176: 15-21 (2006) Molinas S M, Trumper L, Serra E, Elias M M. Evolution of renal function and Na+, K+-ATPase expression during 9. ischaemia-reperfusion injury in rat kidney. MOL CELL BIOCHEM, 287: 33-42 (2006) Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock *10. protein 72 expression and localization in rats following renal ischemia-reperfusion injury. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 291 (4): F806-F811 OCT 2006 1.

11.

Bagshaw SM, Mortis G, Godinez-Luna T, Doig CJ, Laupland KB. Renal recovery after severe acute renal failure. Int J Artif Organs. 2006 Nov;29(11):1023-30

54. Müller V, Szabó A. Nemi különbségek a vesebetegségek progressziójában. Lege Artis Medicinae 2004; 14(1): 26-31 Független idézettség: 1 Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role 1. of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (3-4): 150156 (2005)

55. Vannay A, Fekete A, Müller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo AJ. The effects of histamine and the H2 receptor antagonist ranitidine on ischemia induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor. Kidney Blood Press R 2004; 27: 105-113 IF: 1,067 Független idézettség: 2 * 1. Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal vascular endothelial growth factor mRNA expression and protein level in post-ischaemic rat kidneys. EXP PHYSIOL,

2. * 3. 4. *5.

89: 435-444 (2004) Bates C M, Lin F M. Future strategies in the treatment of acute renal failure: growth factors, stem cells, and other novel therapies. CURR OPIN PEDIATR, 17: 215-220 (2005) Rajnoch J, Lodererova A, Szabo A, Honsova E, Vannay A, Bloudickova S, Matl I, Viklicky O. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: Effect of tacrolimus. TRANSPLANT PROC, 37: 352-354 (2005) Xie H, He S-H. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. WORLD J GASTROENTERO, 11: (19) 2851-2857 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005)

56. Fekete A, Viklicky O, Hubácek JA, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo AJ. Association between Heat Shock Protein (HSP) 70s and Toll like Receptor Polymorphisms with Long-Term Renal Allograft Survival. Transplant Int 2006; 19: 190–196 IF: 1,797

57. Fekete A, Vannay A, Ver A, Rusai K, Muller V, Reusz G, Tulassay T, Szabo AJ. Sex differences in heat shock protein 72 expression and localization in rats following renal ischaemia-reperfusion injury. Am J Physiol Renal Physiol. 2006; 291(4): F806-F811 IF: 4,263 Független idézettség: 1 1.

Bagshaw SM, Mortis G, Godinez-Luna T, Doig CJ, Laupland KB. Renal recovery after severe acute renal failure. Int J Artif Organs. 2006 Nov;29(11):1023-30

Össz IF: 29,259 Független idézettség: 85

A disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények

58. Heemann U, Szabo A, Hamar P, Müller V, Witzke O, Philipp Th. LPS pretreatment protects from renal ischemia/reperfusion injury. Possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000; 156: 287-293 IF: 6,971 Független idézettség: 31 Daemen M A R C, Heemskerk V H, van t Veer C, Denecker G, Wolfs T G A M, Vandenabeele P, Buurman W A. 1. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. CIRCULATION, 102: 1420-1426 (2000) Rayhane N, Fitting C, Lortholary O, Dromer F, Cavaillon J M. Administration of endotoxin associated with 2. lipopolysaccharide tolerance protects mice against fungal infection. INFEC IMMUNITY, 68: 3748-3753 (2000) Rumbeiha W K, Fitzgerald S D, Braselton W E, Roth R A, Pestka J J, Kaneene J B. Augmentation of mercury-induced 3. nephrotoxicity by endotoxin in the mouse. TOXICOLOGY, 151: 103-116 (2000) Ackermann M, Reuter M, Flohe S, Bahrami S, Redl H, Schade F U. Cytokine synthesis in the liver of endotoxin-tolerant 4. and normal rats during hemorrhagic shock. J ENDOTOXIN RES, 7: 105-112 (2001) Colletti L M, Green M. Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous 5. lipopolysaccharide which also increases hepatic TNF production in vivo and in vitro. SHOCK, 16: 312-319 (2001) Ganey P E, Roth R A. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. 6. TOXICOLOGY, 169: 195-208 (2001) Zimmermann C, Ginis I, Furuya K, Klimanis D, Ruetzler C, Spatz M, Hallenbeck J M. Lipopolysaccharide-induced 7. ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. BRAIN RES, 895: 59-65 (2001) 8. Bonventre J V. Kidney ischemic preconditioning. CURR OPIN NEPHROL HYPERTENS, 11: 43-48 (2002) Chatterjee P K, Zacharowski K, Cuzzocrea S, Brown P A J, Stewart K N, Mota Filipe H, Thiemermann C. Lipoteichoic 9. acid from Staphylococcus aureus reduces renal ischemia/reperfusion injury. KIDNEY INT, 62: 1249-1263 (2002) Fernandez D E, Siemers F, Flohe S, Nau M, Schade F U. Effects of endotoxin tolerance on liver function after hepatic 10. ischemia/reperfusion injury in the rat. CRIT CARE MED, 30: (1) 165-170 (2002) * 11. Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo A J. Sexual dimorphism in renal

12. 13.

14. 15. 16. 17. 18. 19. 20. 21. 22. 23. * 24. 25. 26. 27.

* 28. 29. 30.

31. 32. 33. 34.

ischemia-reperfusion injury in rats: Possible role of endothelin. KIDNEY INT, 62: 1364-1371 (2002) Okada M, Yan S F, Pinsky D J. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J, 16: 1861-1868 (2002) Shimizu M, Tamamori Adachi M, Arai H, Tabuchi N, Tanaka H, Sunamori M. Lipopolysaccharide pretreatment attenuates myocardial infarct size: A possible mechanism involving heat shock protein 70-inhibitory kappa B alpha complex and attenuation of nuclear factor kappa B. J THORAC CARDIOVASC SURG, 124: 933-941 (2002) Tremblay J, Chen H F, Peng J Z, Kunes J, Vu M D, Sarkissian S D, Deblois D, Bolton A E, Gaboury L, Marshansky V, Gouadon E, Hamet P. Renal ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. TRANSPLANTATION, 74: 1425-1433 (2002) Wenzel U O, Wolf G, Jacob I, Thaiss F, Helmchen U, Stahl R A K. Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats. KIDNEY INT, 61: 2119-2131 (2002) Wenzel U O, Thaiss F, Helmchen U, Stahl R A K, Wolf G. Angiotensin II infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis. KIDNEY INT, 61: 1020-1029 (2002) Aragno M, Cutrin J C, Mastrocola R, Perrelli M G, Restivo F, Poli G, Danni O, Boccuzzi G. Oxidative stress and kidney dysfunction due to ischemia/reperfusion in rat: Attenuation by dehydroepiandrosterone. KIDNEY INT, 64: 836-843 (2003) Cavaillon J M, Adrie C, Fitting C, Adib Conquy M. Endotoxin tolerance: is there a clinical relevance? J ENDOTOXIN RES, 9: 101-107 (2003) Dirnagl U, Simon R P, Hallenbeck J M. Ischemic tolerance and endogenous neuroprotection. TRENDS NEUROSCI, 26: 248-254 (2003) Friedrich I, Spillner J, Lu E X, Barnscheidt M, Kuss O, Sablotzki A, Schade F U, Borgermann J. Induction of endotoxin tolerance improves lung function after warm ischemia in dogs. AMER J PHYSIOL-LUNG CELL M PH, 284: L224-L231 (2003) Hiki N, Mimura Y, Hatao F, Kojima J, Ogawa T, Tsuji E, Kaminishi M. Sublethal endotoxin administration evokes superresistance to systemic hypoxia in rats. J TRAUMA, 54: 584-589 (2003) Obermaier R, Drognitz O, Grub A, von Dobschuetz E, Schareck W, Hopt U T, Benz S. Endotoxin preconditioning in pancreatic ischemia/reperfusion injury. PANCREAS, 27: E51-E56 (2003) Vaidya V S, Shankar K, Lock E A, Dixon D, Mehendale H M. Molecular mechanisms of renal tissue repair in survival from acute renal tubule necrosis: Role of ERK1/2 pathway. TOXICOL PATHOL, 31: 604-618 (2003) Fekete A, Vannay A, Ver A, Vasarhelyi B, Muller V, Ouyang N, Reusz G, Tulassay T, Szabo A J. Sex differences in the alterations of Na+,K+-ATPase following ischaemia-reperfusion injury in the rat kidney. J PHYSIOL-LONDON, 555: 471-480 (2004) Kariko K, Weissman D, Welsh F A. Inhibition of toll-like receptor and cytokine signaling - A unifying theme in ischemic tolerance. J CEREBR BLOOD FLOW METABOL, 24: 1288-1304 (2004) Kim S H, Lee S M. Expression of hepatic vascular stress genes following ischemia/reperfusion and subsequent endotoxemia. ARCH PHARM RESEARCH, 27: 769-775 (2004) Obermaier R, von Dobschuetz E, Muhs O, Keck T, Drognitz O, Jonas L, Schareck W, Hopt U T, Benz S. Influence of nitric oxide on microcirculation in pancreatic ischemia/reperfusion injury: an intravital microscopic study. TRANSPLANT INT, 17: 208-214 (2004) Vannay A, Fekete A, Muller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo A J. Effects of histamine and the H2 receptor antagonist ranitidine on ischemia-induced acute renal failure: Involvement of IL-6 and vascular endothelial growth factor. KIDNEY BLOOD PRESSURE RES, 27: 105-113 (2004) Day Y J, Huang L, Ye H, Linden J, Okusa M D. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. AMER J PHYSIOL-RENAL PHYSIOL, 288: F722-F731 (2005) Patel N S A, Chatterjee P K, Di Paola R, Mazzon E, Britti D, de Sarro A, Cuzzocrea S, Thiemermann C. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J PHARMACOL EXP THER, 312: 1170-1178 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Godet C, Goujon J M, Petit I, Lecron J C, Hauet T, Mauco G, Carretier M, Robert R. Endotoxin tolerance enhances interleukin-10 renal expression and decreases ischemia-reperfusion renal injury in rats. SHOCK, 25: 384-388 (2006) Lastres Becker I, Cartmell T, Molina Holgado F. Endotoxin preconditioning protects neurones from in vitro ischemia: Role of endogenous IL-1 beta and TNF-alpha. J NEUROIMMUNOL, 173: 108-116 (2006) Ishiyama K, Ohdan H, Tokita D, Shishida M, Tanaka Y, Irei T, Asahara T. Induction of endotoxin tolerance inhibits alloimmune responses. TRANSPLANT IMMUNOLOGY 16 (3-4): 158-165 (2006)

59. Viklicky O, Zou H, Müller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502 IF: 4,035 Független idézettség: 37 * 1.

Vikclicky O, Matl I, Lacha J, Muller V, Szabo A, Heemann U W. Chronic renal allograft rejection: Part II. Possibilities of therapy. CASOPIS LEKARU CESKYCH, 139: (17) 524-528 (2000)

*

*

* *

2. Dumont F J. Everolimus Novartis. CURR OPINION INVEST DRUGS, 2: (9) 1220-1234 (2001) Gaschen L, Audet M, Menninger K, Schuurman H J. Ultrasonographic findings of functioning renal allografts in the 3. cynomolgus monkey (Macaca fascicularis). J MED PRIMATOL, 30: 46-55 (2001) Gregory C R, Katznelson S, Griffey S M, Kyles A E, Berryman E R. Fluvastatin in combination with rad significantly 4. reduces graft vascular disease in rat cardiac allografts. TRANSPLANTATION, 72: 989-993 (2001) Klupp J, Langrehr J M, Junge G, Neuhaus P. Inhibitors of mammalian target of rapamycin. DRUG FUTURE, 26: 5. 1179-1189 (2001) Nashan B. The role of Certican (Everolimus, Rad) in the many pathways of chronic rejection. TRANSPLANT PROC, 6. 33: 3215-3220 (2001) 7. Neuhaus P, Klupp J, Langrehr J M. mTOR inhibitors: An overview. LIVER TRANSPLANT, 7: 473-484 (2001) 8. Pohanka E. New immunosuppressive drugs: An update. CURR OPIN UROLOGY, 11: (2) 143-151 (2001) Vicklicky O, Matl I. Rapamycin: The new immunosuppressant efficient to inhibit the chronic rejection? CASOPSIS 9. LEKARU CESKYCH, 140: (1) 22-25 (2001) Laplante A, Demeule M, Murphy G F, Beliveau R. Interaction of immunosuppressive agents rapamycin and its 10. analogue SDZ-RAD with endothelial P-GP. TRANSPLANT PROC, 34: 3393-3395 (2002) 11. Nashan B. Review of the proliferation inhibitor everolimus. EXPERT OPIN INVESTIG DRUGS, 11: 1845-1857 (2002) 12. Nashan B. Early clinical experience with a novel rapamycin derivative. THER DRUG MONIT, 24: 53-58 (2002) 13. Paul L. New insights in chronic allograft rejection. CURR OPIN UROL, 12: (2) 89-93 (2002) Riederer I, Silva Barbosa S D, Rodrigues M L, Savino W. Local antilaminin antibody treatment alters the rejection 14. pattern of murine cardiac allografts: Correlation between cellular infiltration and extracellular matrix. TRANSPLANTATION, 74: 1515-1522 (2002) Salm P, Taylor P J, Lynch S V, Pillans P I. Quantification and stability of everolimus (SDZ RAD) in human blood by 15. high-performance liquid chromatography-electrospray tandem mass spectrometry. J CHROMATOGR B, 772: 283-290 (2002) Scholten E M, de Fijter J W, Paul L C. Pharmacotherapeutic approach to prevent or treat chronic allograft. Curr Drug 16. Targets - Cardiovascular and Haematological Disorders, 2: (2) 79-96 (2002) Beckmann N, Cannet C, Fringeli Tanner M, Baumann D, Pally C, Bruns C, Zerwes H G, Andriambeloson E, Bigaud M 17. Macrophage labeling by SPIO as an early marker of allograft chronic rejection in a rat model of kidney transplantation. MAGN RESON MED, 49: 459-467 (2003) Belperio J A, Lake K, Tazelaar H, Keane M P, Strieter R M, Lynch J P. Bronchiolitis obliterans syndrome complicating 18. lung or heart-lung transplantation. SEMIN RESPIR CRIT CARE MED, 24: 499-530 (2003) Cahill B C, Somerville K T, Crompton J A, Parker S T, O Rourke M K, Stringham J C, Karwande S V. Early experience 19. with sirolimus in lung transplant recipients with chronic allograft rejection. J HEART LUNG TRANSPLANT, 22: 169176 (2003) Jolicoeur E M, Qi S J, Xu D S, Dumont L, Daloze P, Chen H F. Combination therapy of mycophenolate mofetil and 20. rapamycin in prevention of chronic renal allograft rejection in the rat. TRANSPLANTATION, 75: 54-59 (2003) Lutz J, Zou H Q, Liu S Y, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with 21. everolimus. TRANSPLANTATION, 76: 508-515 (2003) Matsumoto Y, Hof A, Baumlin Y, Hof R P. Differential effect of cyclosporine A and SDZ RAD on neointima formation of 22. carotid allografts in apolipoprotein E-deficient mice. TRANSPLANTATION, 76: 1166-1170 (2003) Pan F, Ebbs A, Wynn C, Erickson L, Jang M S, Crews G, Fisniku O, Kobayashi M, Paul L C, Benediktsson H, Jiang H 23. S. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. TRANSPLANTATION, 75: 1110-1114 (2003) 24. Augustine J J, Hricik D E. Experience with everolimus. TRANSPLANT PROC, 36: 500S-503S (2004) 25. Chapman T M, Perry C M. Everolimus. DRUGS, 64: 861-872 (2004) Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary 26. excretion of bile salts and cholesterol in rats. DIGEST DIS SCI, 49: 30-37 (2004) Formica R N, Lorber K M, Friedman A L, Bia M J, Lakkis F, Smith J D, Lorber M I. The evolving experience using 27. everolimus in clinical transplantation. TRANSPLANT PROC, 36: 495S-499S (2004) Holmes M, Chilcott J, Walters S, Whitby S, Akehurst R. Economic evaluation of everolimus versus mycophenolate 28. mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. TRANSPLANT INT, 17: 182-187 (2004) 29. Pascual J. Everolimus: immunosuppression with antilymphoproliferative therapy. NEFROLOGIA, 24: 112-123 (2004) Starling R C, Hare J M, Hauptman P, Mccurry K R, Mayer H W, Kovarik J M, Schmidli H. Therapeutic drug 30. monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. AM J TRANSPLANT, 4: 2126-2131 (2004) Viklicky O, Bohmova R, Ouyang N, Honsova E, Lodererova A, Mandys V, Vitko S, Lutz J, Heemann U W. Effect of 31. sirolimus on renal ischaemia/reperfusion injury in normotensive and hypertensive rats. TRANSPLANT INT, 17: 432441 (2004) Wang M H, Liu S Y, Ouyang N, Song E W, Lutz J, Heemann U. Protective effects of FTY720 on chronic allograft 32. nephropathy by reducing late lymphocytic infiltration. KIDNEY INT, 66: 1248-1256 (2004) Wu M J, Shu K H, Cheng C H, Chen C H. Sirolimus in chronic allograft nephropathy. TRANSPLANT PROC, 36: 205333. 2055 (2004)

34. 35. 36. 37. * 38. 39. 40. 41. 42.

43.

Baldelli S, Murgia S, Merlini S, Zenoni S, Perico N, Remuzzi G, Cattaneo D. High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. J CHROMATOGR B, 816: 99-105 (2005) Lorber M I, Ponticelli C, Whelchel J, Mayer H W, Kovarik J, Li Y L, Schmidli H. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. CLIN TRANSPLANT, 19: 145152 (2005) Neumayer H H. Introducing everolimus (Certican) in organ transplantation: An overview of preclinical and early clinical developments. TRANSPLANTATION, 79: S72-S75 (2005) Andres V, Castro C, Campistol J M. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. NEPHROL DIALYSIS TRANSPLANT, 21: (2006) Bloudickova S, Rajnoch J, Lodererova A, Honsova E, Viklicky O. Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat. KIDNEY BLOOD PRESSURE RES, 29: 60-66 (2006) Bocchi E A, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, Fernandez D, Fiorelli A, Olaya P, Vulcado N, Perrone S V. Recommendations for use of everolimus after heart transplantation: Results from a Latin-American Consensus Meeting. TRANSPLANT PROC, 38: 937-942 (2006) Dunn C, Croom K F. Everolimus - A review of its use in renal and cardiac transplantation. DRUGS, 66: 547-570 (2006) Pascual J, Boletis I N, Campistol J M. Everolismus (Certican) in renal transplantation: a review of clinical trial data, current usage and fuure directions. TRANSPLANTATION REVIEWS, 20: (1) 1-18 (2006) Webster A C, Lee V W S, Chapman J R, Craig J C. Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. TRANSPLANTATION, 81: 1234-1248 (2006) Serr F, Lauer H, Armann B, Ludwig S, Thiery J, Fiedler M, Ceglarek U, Tannapfel A, Uhlmann D, Hauss J, Witzigmann H. Sirolimus improves early microcirculation, but impairs regeneration after pancreatic ischemiareperfusion injury. AMERICAN JOURNAL OF TRANSPLANTATION 7 (1): 48-56 (2007)

60. Hamar P, Liu S, Viklicky O, Szabo A, Müller V, Heemann U. Cyclosporine A and Azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 2000; 69: 1290-1295 IF: 4,035 Független idézettség: 3 1. 2. *3. 4.

Noris M, Azzollini N, Pezzotta A, Mister M, Benigni A, Marchetti G, Gagliardini E, Perico N, Remuzzi G. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J AMER SOC NEPHROL, 12: 1937-1946 (2001) Afzali B, Taylor A L, Goldsmith D J A. What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations. KIDNEY INT, 68: 2429-2443 (2005) Hamar P, Liptak P, Heemann U, Ivanyi B. Ultrastructural analysis of the Fisher to Lewis rat model of chronic allograft nephropathy. TRANSPLANT INT, 18: 863-870 (2005) Zheng L, Orsida B, Whitford H, Levvey B, Ward C, Walters E H, Williams T J, Snell G I. Longitudinal comparisons of lymphocytes and subtypes between airway wall and bronchoalveolar lavage after human lung transplantation. TRANSPLANTATION, 80: 185-192 (2005)

61. Losonczy G, Kriston T, Szabo A, Müller V, Harvey J, Hamar P, Heemann U, Baylis C. Male gender predisposes to development of endotoxic shock in the rat. Cardiovasc Res 2000; 47: 183-191 IF: 3,783 Független idézettség: 18 1. 2. * 3. 4. 5. 6.

7. 8.

Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? PHARMACOL THER, 91: 179-213 (2001) Morin M J, Karr S M, Faris R A, Gruppuso P A. Developmental variability in expression and regulation of inducible nitric oxide synthase in rat intestine. AMER J PHYSIOL-GASTROINTEST L, 281: G552-G559 (2001) Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo A J. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. KIDNEY INT, 62: 1364-1371 (2002) Okawa T, Vedernokov Y P, Saade G R, Garfield R E. Gender differences in contractile and relaxing responses of aortic rings from lipopolysaccharide-treated rats. GYNECOL ENDOCRINOL, 16: 225-233 (2002) Beery T A. Sex differences in infection and sepsis. Crit Care Nursing Clinics North America, 15: (1) 55-62 (2003) Bindl L, Buderus S, Dahlem P, Demirakca S, Goldner M, Huth R, Kohl M, Krause M, Kuhl P, Lasch P, Lewandowski K, Merz U, Moeller J, Mohamad Y, Peters M, Porz W, Vierzig A, Ruchard J, Scharf J, Varnholt V. Gender-based differences in children with sepsis and ARDS: The ESPNIC ARDS database group. INTENS CARE MED, 29: 17701773 (2003) Helmer K S, Cui Y, Chang L, Dewan A, Mercer D W. Effects of ketamine/xylazine on expression of tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclo-oxygenase-2 in rat gastric mucosa during endotoxemia. SHOCK, 20: 63-69 (2003) Kuebler J F, Yokoyama Y, Jarrar D, Toth B, Rue L W, Bland K I, Wang P, Chaudry I H. Administration of progesterone after trauma and hemorrhagic shock prevents hepatocellular injury. ARCH SURG, 138: 727-734 (2003)

9. * 10.

11. 12. 13. 14. 15. 16. 17. 18. 19. 20.

de la Fuente M, Baeza I, Guayerbas N, Puerto M, Castillo C, Salazar V, Ariznavarreta C, F Tresguerres J A. Changes with ageing in several leukocyte functions of male and female rats. BIOGERONTOLOGY, 5: 389-400 (2004) Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal vascular endothelial growth factor mRNA expression and protein level in post-ischaemic rat kidneys. EXP PHYSIOL, 89: 435-444 (2004) Finamore A, Devirgiliis C, Panno D, D Aquino M, Polito A, Venneria E, Raguzzini A, Coudray C, Mengheri E. Immune response in relation to zinc status, sex and antioxidant defence in Italian elderly population: the ZENITH study. EUR J CLIN NUTR, 59: S68-S72 (2005) Gautier Sauvigne S, Colas D, Parmantier P, Clement P, Gharib A, Sarda N, Cespuglio R. Nitric oxide and steep. SLEEP MED REV, 9: 101-113 (2005) Imahara S D, Jelacic S, Junker C E, O Keefe G E. The influence of gender on human innate immunity. SURGERY, 138: 275-282 (2005) Inaba K, Suzuki S, Ihara H, Sakaguchi T, Baba S, Urano T, Konno H, Nakamura S. Sexual dimorphism in endotoxin susceptibility after partial hepatectomy in rats. J HEPATOL, 42: 719-727 (2005) Pitcher J M, Wang M J, Tsai B M, Kher A, Turrentine M W, Brown J W, Meldrum D R. Preconditioning: Gender effects. J SURG RES, 129: 202-220 (2005) Pitcher J M, Nagy R D, Tsai B M, Wang M J, Kher A, Meldrum D R. Is the preconditioning threshold different in females? J SURG RES, 125: 168-172 (2005) Xu J, Liu L M. The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat. SHOCK, 23: 576-581 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Lipcsey M, Larsson A, Eriksson M B, Sjolin J. Inflammatory, coagulatory and circulatory responses to logarithmic increases in the endotoxin dose in the anaesthetised pig. J ENDOTOXIN RES, 12: 99-112 (2006) Nelson N T, Mahomed A J, Pitcher J M, Tsai B M, Wang M J, Mahomed Y, Brown J W, Crisostomo P, Meldrum D R. Does endogenous testosterone mediate the lower preconditioning threshold in males?. J SURG RES, 131: 86-90 (2006)

62. Reusz GS Szabo A, Ferenc P, Kenesei É, Sallay P, Latta K, Szabó A, Szabó A. Bone metabolism and mineral density following renal transplantation. Arch Dis Child 2000; 83: 146-151 IF: 1,866 Független idézettség: 19 1. 2. 3. 4. 5. 6. 7. 8. 9.

10. 11. 12. 13. 14. 15.

Alon U S. Preservation of bone mass in pediatric dialysis and transplant patients. ADV RENAL REPLACE THER, 8: 191-205 (2001) Behnke B, Kemper M J, Kruse H P, Muller Wiefel D E. Bone mineral density in children with primary hyperoxaluria type I. NEPHROL DIALYSIS TRANSPLANT, 16: 2236-2239 (2001) Kovarik J. Transplantation bone disease: Bone metabolism after kidney transplantation [Transplantationsosteopathie: Knochenstoffwechsel nach nierentransplantation]. JOURNAL FUR MINERALSTOFFWECHSEL, 8: (1) 29-33 (2001) Saland J M, Goode M L, Haas D L, Romano T A, Seikaly M G. The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. AM J TRANSPLANT, 1: 243-250 (2001) Lutz J, Heemann U. Postoperative care for renal transplant recipients. INTERNIST, 43: 1559-1565 (2002) Zlataric D K, Celebic A, Lazic B, Baucic I, Komar D, Stipetic Ovcaricek J, Ibrahimagic L. Influence of age and gender on radiomorphometric indices of the mandible in removable denture wearers. COLLEGIUM ANTROPOL, 26: 259-266 (2002) Daniels M W, Wilson D M, Paguntalan H G, Hoffman A R, Bachrach L K. Bone mineral density in pediatric transplant recipients. TRANSPLANTATION, 76: 673-678 (2003) Zimakas P J A, Sharma A K, Rodd C J. Osteopenia and fractures in cystinotic children post renal transplantation. PEDIAT NEPHROL, 18: 384-390 (2003) El Husseini A A, El Agroudy A E, El Sayed M, Sobh M A, Ghoneim M A. A prospective randomized study for the treatment of bone loss with vitamin D during kidney transplantation in children and adolescents. AM J TRANSPLANT, 4: 2052-2057 (2004) Ruth E M, Weber L T, Schoenau E, Wunsch R, Seibel M J, Feneberg R, Mehls O, Tonshoff B. Analysis of the functional muscle-bone unit of the forearm in pediatric renal transplant recipients. KIDNEY INT, 66: 1694-1706 (2004) Saland J M. Osseous complications of pediatric transplantation. PEDIATR TRANSPLANT, 8: 400-415 (2004) Schoenau E, Land C, Stabrey A, Remer T, Kroke A. The bone mass concept: problems in short stature. EUR J ENDOCRINOLOGY, 151: S87-S91 (2004) Schonau E. The peak bone mass concept: is it still relevant? PEDIAT NEPHROL, 19: 825-831 (2004) Sprague S M, Josephson M A. Bone disease after kidney transplantation. SEMIN NEPHROL, 24: 82-90 (2004) Bottcher J, Pfeil A, Rosholm A, Petrovitch A, Seidl B E, Malich A, Schafer M L, Kramer A, Mentzel H J, Lehmann G,

16. 17. 18. 19.

Hein G, Kaiser W A. Digital x-ray radiogrammetry combined with semiautomated analysis of joint space widths as a new diagnostic approach in rheumatoid arthritis - A cross-sectional and longitudinal study. ARTHRITIS RHEUM, 52: 3850-3859 (2005) Goksen D, Darcan S, Kara P, Mir S, Coker M, Kabasakal C. Bone mineral density in pediatric and adolescent renal transplant patients: How to evaluate. PEDIATR TRANSPLANT, 9: 464-469 (2005) Leonard M B. Assessment of bone mass following renal transplantation in children. PEDIAT NEPHROL, 20: 360-367 (2005) Mentzel H J, John U, Boettcher J, Malich A, Pfeil A, Vollandt R, Misselwitz J, Kaiser W A. Evaluation of bonemineral density by digital X-ray radiogrammetry (DXR) in pediatric renal transplant recipients. PEDIAT RADIOL, 35: 489-494 (2005) Zisman A L, Sprague S M. Bone disease after kidney transplantation. ADV CHRONIC KIDNEY DIS, 13: 35-46 (2006)

63. Müller Veronika, Szabó Attila, Becker Gerold, Delfs Michael, Veres Tibor, Albrecht Karl-Heinz, Philipp Thomas, Heemann Uwe. Húgyúti fertőzések hatása a transzplantált vese chronicus kilökődésére. Hypertonia és Nephrologia 2000; 4(3): 141-145

64. Viklicky O, Muller V, Zou H, Szabo A, Vitko S, Heemann U. RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection. Transplant P 2001; 33(3): 2320-2321 IF:0,568 Független idézettség: 2 1. Dumont FJ. Everolimus novartis. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2: (9) 1220-1234 (2001) Neff G W, Montalbano M, Tzakis A G. Ten years of sirolimus therapy in orthotopic liver transplant recipient. 2. TRANSPLANT PROC, 35: 209S-216S (2003) Viklicky O, Bohmova R, Ouyang N, Honsova E, Lodererova A, Mandys V, Vitko S, Lutz J, Heemann U W. Effect of *3. sirolimus on renal ischaemia/reperfusion injury in normotensive and hypertensive rats. TRANSPLANT INT, 17: 432-441 (2004) Bloudickova S, Rajnoch J, Lodererova A, Honsova E, Viklicky O. Mycophenolate mofetil ameliorates accelerated *4. progressive nephropathy in rat. KIDNEY BLOOD PRESSURE RES, 29: 60-66 (2006)

65. Hamar P, Szabo A, Muller V, Heemann U. The involvement of activated T-cells and growth-factor production in the early and late phase of chronic kidney allograft nephropathy in rats. Transpl Int 2002; 15(9-10): 446-454 IF: 2,520 Független idézettség: 5 1. Tervaert JWC, de Leeuw PW. Renal protection from glomerular fibrosis. J HYPERTENS, 21: (4) 687-689 (2003) Rajnoch J, Viklicky O. Angiogenesis and organ transplantation. FOLIA MICROBIOLOGICA, 49: (5) 499-505 2. (2004) Adams J, Kiss E, Arroyo AB, Bonrouhi M, Sun Q, Li Z, Gretz N, Schnitger A, Zouboulis CC, Wiesel M, Wagner 3. J, Nelson PJ, Grone HJ. 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. AM J PATHOL, 167: (1) 285-298 (2005) Doege C Koch M Heratizadeh A, Sotonyi P, Mengel M, Nashan B. Chronic allograft nephropathy in athymic 4. nude rats after adoptive transfer of primed T lymphocytes. TRANSPLANT INT, 18: (8) 981-991 (2005) Hamar P, Liptak P, Heemann U, Ivanyi B. Ultrastructural analysis of the Fisher to Lewis rat model of chronic allograft * 5. nephropathy. Transplant International, 18: (7) 863-870 (2005) Minguillon J Morancho B Kim SJ, Lopez-Botet M, Aramburu J. Concentrations of cyclosporin A and FK506 6.

that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1. J LEUKOCYTE BIOL, 77: (5) 748758 (2005)

66. Losonczy Gy,, Kriston T, Szabó A, Müller V, Harvey J, Heemann U, Baylis C. Nemi különbségek a kísérletes endotoxin sokk kialakulásában. A nitrogén-monoxid szintézis jelentősége. Medicina Thoracalis 2002; 55: 66-73

67. Erdely A, Wagner L, Müller V, Szabo A, Baylis C. Protection of Wistar Furth rat from renal disease is associated with maintained renal nitric oxide. J Am Soc Nephrol 2003; 14(10):2526-33 IF: 7,499 Független idézettség: 7 * 1.

Erdely A, Freshour G, Maddox D A, Olson J L, Samsell L, Baylis C. Renal disease in rats with Type 2 diabetes is associated with decreased renal nitric oxide production. DIABETOLOGIA, 47: 1672-1676 (2004)

* 2. 3. 4. 5. 6. * 7. * 8. * 9. 10. * 11. 12.

13.

* 14.

Erdely A, Freshour G, Smith C, Engels K, Olson J L, Baylis C. Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. AMER J PHYSIOL-RENAL PHYSIOL, 287: F81-F89 (2004) Fliser D, Kronenberg F, Kielstein J T, Morath C, Bode Boger S M, Haller H, Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J AMER SOC NEPHROL, 16: 24562461 (2005) Ji H, Pesce C, Zheng W, Kim J, Zhang Y H, Menini S, Haywood J R, Sandberg K. Sex differences in renal injury and nitric oxide production in renal wrap hypertension. AMER J PHYSIOL-HEART CIRC PHY, 288: H43-H47 (2005) Lee T M, Lin M S, Tsai C H, Chang N C. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT(1) receptor blockers. KIDNEY INT, 68: 779-787 (2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Baylis C. Acute and long-term effects of modified hemoglobin (HBOC-201) in a rat model of hypertension and chronic kidney disease. TRANSFUSION, 46: 1104-1111 (2006) Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. NAT CLIN PRACT NEPHROL, 2: 209-220 (2006) Baylis C. Nitric oxide deficiency in chronic renal disease. EUR J CLIN PHARMACOL, 62: 123-130 (2006) Brunini T M C, Yaqoob M M, Roberts N B, Ellory J C, Moss M B, Siqueira M A S, Mann G E, Ribeiro A C M. Characterization of cationic amino acid transport systems in rat erythrocytes: Lack of effect of uraemia on L-arginine influx. CLIN EXP PHARMACOL PHYSIOL, 33: 702-707 (2006) Erdely A, Freshour G, Baylis C. Resistance to renal damage by chronic nitric oxide synthase inhibition in the WistarFurth rat. AMER J PHYSIOL-REGUL INTEGR C, 290: R66-R72 (2006) Ochodnicky P, Vettoretti S, Henning R H, Buikema H, van Dokkum R P E, de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J NEPHROLOGY, 19: 246-258 (2006) Schwartz I F, Ayalon R, Chernichovski T, Reshef R, Chernin G, Weinstein T, Litvak A, Levo Y, Schwartz D. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. KIDNEY INT, 69: 298303 (2006) Tain YL, Muller V, Szabo A, Dikalova A, Griendling K, Baylis C. Lack of long-term protective effect of antioxidant/anti-inflammatory therapy in transplant-induced ischemia/reperfusion injury. AMERICAN JOURNAL OF NEPHROLOGY 26 (3): 213-217 2006

68. Rajnoch J, Lodererova A, Szabo A, Honsova E, Vannay A, Bloudickova S, Matl I, Viklicky O. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: Effect of tacrolimus. Transplant P 2005; 37(1): 352-354 IF: 0,799 Független idézettség: 1 1.

Mcalister V C. Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. ANN INTERN MED, 144: 226-227 (2006)

69. Tain YL, Muller V, Szabo A, Dikalova A, Griendling K, Baylis C. Lack of Long-Term Protective Effect of Antioxidant/Anti-Inflammatory Therapy in Transplant-Induced Ischemia/Reperfusion Injury. Am J Nephrol. 2006; 26(3): 213-217 IF: 2,459

70. Reusz György, Szabó Attila, Remport Ádám, Szabó József, Járay Jenő. Veseátültetés gyermekkorban. Gyermekgyógyászati szemle 2006; 11(3-4): 99-108 Össz impakt faktor: 34,535 Független idézettség: 123

Nem a disszertáció témájában megjelent első- vagy utolsószerzős közlemények

71. Molnar Z, Farkas V, Nemes L, Reusz GS, Szabo AJ. Hyponatraemic seizures resulting from inadequate post-operative fluid intake following a single dose of desmopressin. Nephrol Dial Transpl 2005; 20: 2265-2267 IF: 2,976 Független idézettség: 1

1.

Radó János, Apor Péter. Szakirodalmi válogatások a vízintoxikációról. (Vízintoxikáció sportolás során, kórházban, börtönben, gyermekbántalmazás következtében, gyógyszerek hatáására). Hypertonia és Nephrologia, 10 (1): 44-49 (2006)


Nem a disszertáció témájában a PhD értekezést követően megjelent társszerzős közlemények

72. Miltényi G, Tory K, Stubnya G, Sallay P, Dobos M, Vásárhelyi B, Szabo A, Reusz G. Monitoring cardiovascular changes during hemodialysis in children. Pediatr Nephrol 2001; 16: 19-2 IF:1,391 Független idézettség: 1 1.

Chavers B, Schnaper H W. Risk factors for cardiovascular disease in children on maintenance dialysis. ADV RENAL REPLACE THER, 8: 180-190 (2001)

73. Tory K, Tóth-Heyn P, Szabo A, Stubnya G, Reusz GS. Signs of autonomic neuropathy in childhood uremia. Pediatr Nephrol 2001; 16: 25-28 IF: 1,391 1. 2. 3. * 4. * 5.


Rangari M, Sinha S, Kapoor D, Mohan J C, Sarin S K. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. AMER J GASTROENTEROL, 97: 707-713 (2002) Robinson T G, Carr S J. Cardiovascular autonomic dysfunction in uremia. KIDNEY INT, 62: 1921-1932 (2002) Neto E P S, Neidecker J, Lehot J J. To understand blood pressure and heart rate variability. ANN FR ANESTH REANIM, 22: 425-452 (2003) Tory K, Suveges Z, Horvaath E, Bokor E, Sallay P, Berta K, Szabo A, Tulassay T, Reusz G S. Autonomic dysfunction in uremia assessed by heart rate variability. PEDIAT NEPHROL, 18: 1167-1171 (2003) Tory K, Horvath E, Suveges Z, Fekete A, Sallay P, Berta K, Szabo T, Szabo A J, Tulassay T, Reusz G S. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trial. CLIN NEPHROL, 61: 316-323 (2004)

74. Hamar P, Peti-Peterdi J, Szabo A, Becker G, Flach R, Rosivall L, Heemann U. Interleukin-2-dependent mechanism are involved in the development of glomerulosclerosis after partial renal ablation in rats. Exp Nephrol 2001; 9(2): 133-141 IF:1,881 Független idézettség: 5 1. 2. * 3. 4. 5. 6.

Ota T, Tamura M, Osajima A, Doi Y, Kudo H, Anai H, Miyazaki M, Nishino T, Nakashima Y. Expression of monocyte chemoattractant protein-1 in proximal tubular epithelial cells in a rat model of progressive kidney failure. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 140: 43-51 (2002) Sairam VK, Kalia A, Rajaraman S, Travis LB. Secondary resistance to cyclosporin A in children with nephrotic syndrome. PEDIATRIC NEPHROLOGY, 17: 842-846 (2002) Antus B, Hamar P, Kokeny G, Szollosi Z, Mucsi I, Nemes Z, Rosivall L. Estradiol is nephroprotective in the rat remnant kidney. NEPHROLOGY DIALYSIS TRANSPLANTATION, 18: 54-61 (2003) Suzuki K, Kanabayashi T, Nakayama H, Doi K. Effects of tacrolimus and dexamethasone on tubulointerstitial fibrosis in mercuric chloride treated Brown Norway rats. EXP TOXICOL PATHOL, 55: 197-207 (2003) Yatsu T, Sanagi M, Fujimori A, Tomura Y, Hayashi K, Tanahashi M, Inagaki O. Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction. PHARMACOLOGICAL RESEARCH, 47: 243-252 (2003) Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. BIRTH DEFECTS RES B, 68: (2) 111-120 (2003)

75. Tory K, Horváth E, Süveges Z, Fekete A, Sallay P, Berta K, Szabó T, Szabo AJ, Tulassay T, Reusz GS. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a doubleblind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol 2004; 61(5): 316-323 IF: 1,316

76. Reusz György, Szabó Attila, Fekete Andrea. Idiopathiás nephrosis szindróma gyermekkorban. Orvosi Hetilap 2006; 147(47): 2251-2260

77. Karoly E, Fekete A, Banki NF, Szebeni B, Vannay A, Szabo AJ, Tulassay T, Reusz GS. Heat Shock Protein 72 (HSPA1B) Gene Polymorphism and Toll-Like Receptor (TRL) 4 Mutation are Associated with Increased Risk of Urinary Tract Infection in Children. Ped Res 2007 (közlésre elfogadva) IF: 2,875 Össz impakt faktor: 8,854 Független idézettség: 9

A PhD értekezést megelőzően megjelent közlemények A disszertáció témájában a PhD értekezést megelőzően megjelent első- vagy utolsószerzős közlemények

78. Szabo A, Viazov S, Heemann U., Kribben A., Philipp Th., Roggendorf M. GBV-C/HGV infection in renal dialysis and transplant patients. Nephrol Dial Transpl 1997; 12: 2380-2384 IF: 1,682 Független idézettség: 17

**1. 2.

3. 4. 5. 6. 7.

**8. 9. 10.

11. 12. 13. 14. 15. 16. 17.

18. 19.

Szabo A, Sallay P, Kribben A, Ross S, Roggendorf M, Tulassay T, Phillipp T, Heemann U. Hepatitis G virus infection in children on dialysis and after renal transplantation PEDIATR NEPHROL, 12: 93-95 (1998) Dalekos G N, Zervou E K, Elisaf M, Boumba D S, Katopodis K, Sferopoulos G S, Siamopoulos K C, Tsianos E V. Increased prevalence of markers of GBV-C/HGV infection in a selected cohort of haemodialysis patients negative for other blood-borne viruses. NEPHROL DIAL TRANSPL, 14: 255-256 (1999) Desassis J F, Laperche S, Girault A, Kolko A, Bouchardeau F, Zins B, Poignet J L, Courouce A M. Prevalence of present and past hepatitis G virus infection in a French haemodialysis centre. NEPHROL DIAL TRANSPL, 14: 26922697 (1999) Fabrizi F, Martin P. GBV-C/HGV infection in end-stage renal disease. J NEPHROL, 12: 131-139 (1999) Gartner B C, Kaul H, Neutzling A G, Sauter M, Mueller Lantzsch N, Kohler H. High prevalence of hepatitis G virus (HGV) infections in dialysis staff. NEPHROL DIAL TRANSPL, 14: 406-408 (1999) Goubau P, Liu H F, Goderniaux E, Burtonboy G. Influence of CD4(+) lymphocyte counts on GB virus C hepatitis G virus carriership in HIV-positive individuals. J MED VIROL, 57: 367-369 (1999) Martin P, Fabrizi F, Dixit V, Brezina M, Gerosa S, Russell J, Conrad A, Gitnick G. Epidemiology and natural history of hepatitis G virus infection in chronic hemodialysis patients. AM J NEPHROL, 19: 535-540 (1999) Ross R S, Viazov S, Varenholz C, Roggendorf M. Inquiries on intraspousal transmission of hepatitis C virus: benefits and limitations of genome sequencing and phylogenetic analysis. FORENSIC SCI INT, 100: 69-76 (1999) Rostaing L, Izopet J, Arnaud C, Rumeau J L, Duffaut M, Cisterne J M, Durand D. Long-term impact of co-infection by hepatitis G virus in hepatitis C virus positive renal transplant patients. NEPHROLOGIE, 20: 165-170 (1999) Rostaing L, Izopet J, Arnaud C, Cisterne J M, Alric L, Rumeau J L, Duffaut M, Durand D. Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. TRANSPLANTATION, 67: 556-560 (1999) Barril G, Lopez Alcorocho J M, Bajo A, Ortiz Movilla N, Sanchez Tomero J A, Bartolome J, Selgas R, Carreno V. Prevalence of TT virus in serum and peripheral mononuclear cells from a CAPD population. PERITON DIALYSIS INT, 20: 65-68 (2000) Fabrizi F, Lunghi G, Pozzi C, Colzani S, Tentori F, Del Vecchio L, Corti M, Pagano A, Locatelli F. GBV-C/HGV infection in end-stage renal disease: a serological and virological survey. J NEPHROL, 13: 68-74 (2000) Vurusic B, Grahovac B, Drazic V, Bingulac-Popovic J. Prevalence and clinical significance of hepatitis G virus infection in hemodialysis patients. PERIOD BIOL, 102: 25-28 (2000) Svirtlih N. GB virus-C/ hepatitis G virus: A hepatitis-virus or not, is the dilemma finally solved? ARCHIVES OF GASTROENTEROHEPATOLOGY, 20: 25-34 (2001) Villari P, Ribera G, Nobile C G A, Torre I, Ricciardi G. Antibodies to the E2 protein of GB virus C hepatitis G virus: Prevalence and risk factors in different populations in Italy. INFECTION, 29: 17-23 (2001) Fabrizi F, de Vecchi A F, Lunghi G, Finazzi S, Bisegna S, Ponticelli C. Epidemiology of GB virus C/hepatitis G virus infection in patients on peritoneal dialysis. PERITON DIALYSIS INT, 22: 405-410 (2002) Yuen M F, Chan T M, Yip T P S, Yuen J C H, Ho S K N, Lai C L. Prevalence and significance of hepatitis GB virusC/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. DIGEST DIS SCI, 47: 432-437 (2002) Ramos R, Carneiro M A, Teles S A, Dias M A, Cardoso D D P, Lampe E, Yoshida C F T, Martins R M B. GB virus C/hepatitis G virus infection in dialysis patients and kidney transplant recipients in Central Brazil. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 99: 639-643 (2004) Kumar D, Arora A, Singh N P, Kohli R, Kar P, Das B C. Hepatitis G virus infection in hemodialysis patients from urban Delhi. RENAL FAILURE, 27: 87-93 (2005)

79. Szabo A, Sallay P, Kribben A, Ross S, Philipp Th, Roggendorf M., Tulassay T., Heemann U. GBVC/HGV infection in children on dialysis and after renal transplantation. Pediatr Nephrol 1998; 12: 93-95 IF: 1,158 Független idézettség: 3 1. 2.

Komatsu H, Fujisawa T, Inui A, Sogo T, Morinishi Y, Miyagawa Y, Inui M. GBV-C/HGV infection in children with chronic hepatitis C. J MED VIROL, 59: 154-159 (1999) Siebert D J, Bowden D D, Tracy S L, Hardikar W. Prevalence of hepatitis G/GBV-C in a healthy paediatric population. J PAEDIATR CHILD H, 38: 423-423 (2002)

Yuen M F, Chan T M, Yip T P S, Yuen J C H, Ho S K N, Lai C L. Prevalence and significance of hepatitis GB virusC/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. DIGEST DIS SCI, 47: 432-437 (2002)

3.

80. Szabo A, Heemann U. Ischemia/reperfusion and chronic allograft rejection. Transplant P 1998; 30: 4281-4284 IF: 0,740 1. 2. * 3. 4. * 5. 6. 7. 8.

9. * 10. 11. 12. 13. 14. 15. 16.

*17. 18. 19. 20. 21. * 22. 23. 24.


Fan C G, Zwacka R M, Engelhardt J F. Therapeutic approaches for ischemia/reperfusion injury in the liver. J MOL MED-JMM, 77: 577-592 (1999) Goujon J M, Vandewalle A, Baumert H, Carretier M, Hauet T. Influence of cold-storage conditions on renal function of autotransplanted large pig kidneys. KIDNEY INT, 58: 838-850 (2000) Heemann U, Szabo A, Hamar P, Muller V, Witzke O, Lutz J, Philipp T. Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury - Possible connection to an interleukin-6-dependent Pathway. AM J PATHOL, 156: 287-293 (2000) Nilsson B, Friman S, Wallin M, Gustafsson B, Delbro D. The liver protective effect of ischemic preconditioning may be mediated by adenosine. TRANSPLANT INT, 13: S558-S561 (2000) Reusz G S, Szabo A J, Peter F, Kenesei E, Sallay P, Latta K, Szabo A, Szabo A, Tulassay T. Bone metabolism and mineral density following renal transplantation. ARCH DIS CHILD, 83: 146-151 (2000) Wada Takahashi S, Tamura K. Actions of reactive oxygen species on AH/type 2 myenteric neurons in guinea pig distal colon. AM J PHYSIOL-GASTR L, 279: G893-G902 (2000) Bohmova R, Viklicky O. Renal ischemia-reperfusion injury: an inescapable event affecting kidney transplantation outcome. FOLIA MICROBIOL, 46: 267-276 (2001) Hauet T, Baumert H, Goujon J M, Ben Amor I, Richer J P, Carretier M, Eugene M, Morin D, Tillement J P. Preservation conditions influence long-term renal function following autotransplantation. THERAPIE, 56: 563-567 (2001) Wagener F A D T G, Eggert A, Boerman O C, Oyen W J G, Verhofstad A, Abraham N G, Adema G, van Kooyk Y, de Witte T, Figdor C G. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. BLOOD, 98: 1802-1811 (2001) Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo A J. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. KIDNEY INT, 62: 1364-1371 (2002) Preston E, Kirk AD. Context-based therapy: A conceptual framework for transplantation tolerance. TRANSPORT REV, 16: (3) 142-162 (2002) Joosten S A, van Kooten C, Paul L C. Pathogenesis of chronic allograft rejection. TRANSPLANT INT, 16: 137-145 (2003) Smit-van Oosten A, Stegeman CA, van Goor H. RAS blockade in experimental renal transplantation. benefits and limitations. CURR DRUG TARGETS, 3: (1) 73-79 (2003) Faure J P, Petit I, Zhang K Q, Dutheil D, Doucet C, Favreau F, Eugene M, Goujon J M, Tillement J P, Mauco G, Vandewalle A, Hauet T. Protective roles of polyethylene glycol and trimetazidine against cold ischemia and reperfusion injuries of pig kidney graft. AM J TRANSPLANT, 4: 495-504 (2004) Harada N, Hatano E, Koizumi N, Nitta T, Yoshida M, Yamamoto N, Brenner D A, Yamaoka Y. Akt activation protects rat liver from ischemia/reperfusion injury. J SURG RES, 121: 159-170 (2004) Tsuchiya K, Takiguchi Y, Okamoto M, Izawa Y, Kanematsu Y, Yoshizumi M, Tamaki T. Malfunction of vascular control in lifestyle-related diseases: Formation of systemic hemoglobin-nitric oxide complex (HbNO) from dietary nitrite. J PHARMACOL SCI, 96: 395-400 (2004) Vannay A, Fekete A, Muller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabo A J. Effects of histamine and the H2 receptor antagonist ranitidine on ischemia-induced acute renal failure: Involvement of IL-6 and vascular endothelial growth factor. KIDNEY BLOOD PRESS R, 27: 105-113 (2004) Nishikawa M. Development of cell-specific targeting systems for drugs and genes. BIOL PHARM BULL, 28: 195-200 (2005) Okamoto M, Tsuchiya K, Kanematsu Y, Izawa Y, Yoshizumi M, Kagawa S, Tamaki T. Nitrite-derived nitric oxide formation following ischemia-reperfusion injury in kidney. AM J PHYSIOL-RENAL, 288: F182-F187 (2005) Pompermayer K, Souza D G, Lara G G, Silveira K D, Cassali G D, Andrade A A, Bonjardim C A, Passaglio K T, Assreuy J, Cunha F Q, Vieira M A R, Teixeira M M. The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats. KIDNEY INT, 67: 1785-1796 (2005) Renner A, Sagstetter M R, Harms H, Lange V, Gotz M E, Elert O. Formation of 4-hydroxy-2-nonenal protein adducts in the ischemic rat heart after transplantation. J HEART LUNG TRANSPL, 24: 730-736 (2005) Schmaderer C, Lutz J, Stangl M, Heemann U. Ischemia-reperfusion injury after kidney transplantation; [Ischaa mie/reperfusionsschaden nach nierentransplantation]. TRANSPLANTLINC, (10) 15-25 (2005) Uehara T, Bennett B, Sakata S T, Satoh Y, Bilter G K, Westwick J K, Brenner D A. JNK mediates hepatic ischemia reperfusion injury. J HEPATOL, 42: 850-859 (2005) Araki M, Fahmy N, Zhou L M, Kumon H, Krishnamurthi V, Goldfarb D, Modlin C, Flechner S, Novick A C, Fairchild R L. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. TRANSPLANTATION, 81:

25. 26. * 27. 28.

783-788 (2006) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Bolad I A, Robinson D R, Webb C, Hamour I, Burke M M, Banner N R. Impaired left ventricular systolic function early after heart transplantation is associated with cardiac allograft vasculopathy. AM J TRANSPLANT, 6: 161-168 (2006) Fekete A, Viklicky O, Hubacek J A, Rusai K, Erdei G, Treszl A, Vitko S, Tulassay T, Heemann U, Reusz G, Szabo A J. Association between heat shock protein 70s and Toll-like receptor polymorphisms with long-term renal allograft survival. TRANSPLANT INT, 19: 190-196 (2006) Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. TRANSPLANT IMMUNOLOGY 16 (3-4): 148-157 (2006)

81. Szabo A, Patschan O, Kuttler B., Müller V., Philipp Th, Rettig R., Heemann U. Hypertension accelerates the pace of chronic allograft rejection in rat. Transplant Int 1998; S11: 10-14 IF: 1,870 1. 2. 3.

4.

5.

6.


Olyaei A J, Demattos A M, Bennett W M. A practical guide to the management of hypertension in renal transplant recipients. DRUGS, 58: 1011-1027 (1999) Schindler R, Tanriver Y, Frei U. Hypertension and allograft nephropathy - cause, consequence, or both? NEPHROL DIAL TRANSPL, 15: 8-10 (2000) Pratschke J, Paz D, Wilhelm M J, Laskowski I, Kofla G, Vergopoulos A, Mackenzie H J, Tullius S G, Neuhaus P, Hancock W W, Volk H D, Tilney N L. Donor hypertension increases graft immunogenicity and intensifies chronic changes in long-surviving renal allografts. TRANSPLANTATION, 77: 43-48 (2004) Velic A, Hirsch J R, Bartel J, Thomas R, Schroter R, Stegemann H, Edemir B, August C, Schlatter E, Gabriels G. Renal transplantation modulates expression and function of receptors and transporters of rat proximal tubules. J AM SOC NEPHROL, 15: 967-977 (2004) Velic A, Gabriels G, Hirsch J R, Schroter R, Edemir B, Paasche S, Schlatter E. Acute rejection after rat renal transplantation leads to downregulation of Na+ and water channels in the collecting duct. AM J TRANSPLANT, 5: 1276-1285 (2005) Ayed K, Ayed Jendoubi S, Ben Abdallah T, Bardia R, Gorgi Y, Sfar I, Dhrif B, Abderrahim E, Kheder A. Polymorphism of the renin-angiotensin-aldosterone system in patients with chronic allograft dysfunction. TRANSPL IMMUNOL, 15: 303-309 (2006)

82. Szabó A, Heemann U, Müller V, Reusz Gy, Sallay P, Viazov S, Tulassay T. Hepatitis G vírus infekció vesetranszplantált és dializált gyermek és felnőtt betegekben. Orvosi Hetilap 1999; 140(29): 1619-1623 Független idézettség: 4 1. 2. 3. 4.

Takacs M, Rusvai E, Brojnas J, Toth G, Szomor K, Toth E, Szendroi A, Berencsi G. Introduction of hepatitis G and TT virus diagnostics in Hungary. LEGE ARTIS MEDICINAE, 11: (4) 274-282 (2001) Takacs M, Szomor K N, Szendroi A, Dencs A, Brojnas J, Rusvai E, Berencsi G. Prevalence of GB virus C/hepatitis G virus in Hungary. FEMS IMMUNOL MED MICROBIOL, 34: 283-287 (2002) Keresztes K, Takacs M, Horanyi M, Miltenyi Z, Illes A. HCV and HGV infection in Hodgkin's disease. PATHOL ONCOL RES, 9: 222-225 (2003) Par A, Takacs M, Brojnas J, Berencsi G, Paal M, Horanyi M, Miseta A, Hegedus G, Mozsik G, Hunyady B. Viral coinfections in hepatitis C virus (HCV) infection: HBV, HGV and TTV studies [Viruskoinfekciok kronikus hepatitis Cvirus-fertozesben: HBV-, GBV-C/HGV- es TTV-vizsgalatok]. ORVOSI HETILAP, 145: (19) 987-992 (2004)

83. Szabó A, Müller V, Patschan O, Kuttler B, Rettig R, Reusz G, Heemann U. Hypertónia hatása a transzplantált vese krónikus kilökődésére. Hypertonia és Nephrologia 1999; 3(3): 127-131 Össz impakt faktor: 5,450 Független idézettség: 52

A disszertáció témájában a PhD értekezést megelőzően megjelent társszerzős közlemények

84. Müller V, Hamar P, Szabo A, Knust E, Vogelsang M, Heemann U. Effect of mycophenolate mofetil on the in-vivo infiltration of lymphocytes in the rat remnant kidney. Transplant P 1998, 30: 982 IF: 0,740 Független idézettség: 11

1. Jayne D. Non-transplant uses of mycophenolate mofetil. CURR OPIN NEPHROL HYPERTENS, 8: 563-567 (1999) Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. IMMUNOPHARMACOLOGY, 47: 85-118 2. (2000) Ojo A O, Meier Kriesche H U, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan 3. B. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. TRANSPLANTATION, 69: 2405-2409 (2000) Helderman J H. General considerations of immunosuppressive therapies - Efficacy versus toxicity. TRANSPLANT PROC, 4. 33: 2S-3S (2001) Sato N, Shiraiwa K, Kai K, Watanabe A, Ogawa S, Kobayashi Y, Yamagishi-Imai H, Utsunomiya Y, Mitarai T. 5. Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. NEPHRON, 89: 177-185 (2001) Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. INT J CLIN 6. PHARM THERAPEUTICS, 41: 465-469 (2003) Offermann G. Five-year results of renal transplantation on immunosuppressive triple therapy with mycophenolate 7. mofetil. CLIN TRANSPLANT, 17: 43-46 (2003) Paskalev E, Simeonov P. Mycophenolate mophetil in renal transplantation. NEPHROLOGY, DIALYSIS AND 8. TRANSPLANTATION, 9: (4) 39-43 (2003) Lenz O, Fornoni A, Contreras G. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus 9. nephritis. DRUGS, 65: 2429-2436 (2005) Bloudickova S, Rajnoch J, Lodererova A, Honsova E, Viklicky O. Mycophenolate mofetil ameliorates accelerated 10. progressive nephropathy in rat. KIDNEY BLOOD PRESS R, 29: (1) 60-66 (2006) van Leuven S I, Kastelein J J P, Allison A C, Hayden M R, Stroes E S G. Mycophenolate mofetil (MMF): Firing at the 11. atherosclerotic plaque from different angles? CARDIOVASC RES, 69: 341-347 (2006)

85. Witzke O, Becker G, Erhard J, Lütkes P, Szabo A, Philipp Th, Heemann U. Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation. Clin Nephrol 1998, 49: 2427 IF: 1,323 Független idézettség: 3 Ader J L, Rostaing L. Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. CURR OPIN NEPHROL HYPERTENS, 7: 539-545 (1998) Plosker G L, Foster R H. Tacrolimus - A further update of its pharmacology and therapeutic use in the management of organ transplantation. DRUGS, 59: 323-389 (2000) Hymes L C, Warshaw B L. Tacrolimus rescue therapy for children with acute renal transplant rejection. PEDIAT NEPHROL, 16: 990-992 (2001)

1. 2. 3.

86. Müller V, Hamar P, Vogelsang M, Szabó A, Philipp T, Heemann U. In-vivo migration of lymphocytes in chronically rejecting rat kidney allografts: essential role of CD18. Transplant Int 1999; 12: 145-151 IF: 1,599 Független idézettség: 2 * 1. * 2. * 3. 4. * 5. 6.

Hamar P, Liu S Y, Viklicky O, Szabo A, Muller V, Heemann U. Cyclosporine A and azathioprine are equipotent in chronic kidney allograft rejection. TRANSPLANTATION, 69: 1290-1295 (2000) Hamar P, Szabo A, Muller V, Heemann U. Involvement of interleukin-2 and growth factors in chronic kidney allograft rejection in rats. TRANSPLANT PROC, 33: 2160-2162 (2001) Song E W, Zou H Q, Yao Y S, Proudfoot A, Antus B, Liu S Y, Jens L, Heemann U. Early application of Met-RANTES ameliorates chronic allograft nephropathy. KIDNEY INT, 61: 676-685 (2002) Noti J D. Expression and function of the leukocyte integrins in organ transplant rejection. CURR MEDICINAL CHEM, 11: 477-490 (2004) Wang M H, Liu S Y, Ouyang N, Song E W, Lutz J, Heemann U. Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration. KIDNEY INT, 66: 1248-1256 (2004) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005)

87. Müller V, Szabó A, Viklicky O, Portl S, Heemann U. Sex hormones and gender related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55: 2011-2020 IF: 3,807 Független idézettség: 27 Labarrere C A, Nelson D R, Miller S J, Nieto J M, Conner J A, Pitts D E, Kirlin P C, Halbrook H G. Value of serum1. soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. CIRCULATION, 102: 1549-1555 (2000) * 2. Viklicky O, Matl I, Lacha J, Muller V, Szabo, Heemann U W. Chronic renal allograft rejection. Part II. Possibilities of

* 3. 4. 5. 6. 7. 8. * 9. 10. 11. 12. 13. 14. 15. * 16. 17. * 18. 19. 20. 21. 22. 23. * 24. 25. * 26. * 27. 28. 29. 30. 31. 32.

therapy. Casopis Lekaru Ceskych, 139: (7) 524-528 (2000) Antus B, Yao Y S, Liu S Y, Song E W, Lutz J, Heemann U. Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone. KIDNEY INT, 60: 1955-1963 (2001) Dubey R K, Jackson E K. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. AMER J PHYSIOL-RENAL PHYSIOL, 280: F365-F388 (2001) Lane P H, Snelling D M, Babushkina Patz N, Langer W J. Sex differences in the renal transforming growth factor-beta 1 system after puberty. PEDIAT NEPHROL, 16: 61-68 (2001) Leendert C P, Fijter J W, Sijpkens. Chronic renal transplant rejection. In: Morris P.J. (szerk.) Kidnay Transplantation, Philadelphia: Saunders, 2001. 408-418. Meier Kriesche H U, Ojo A O, Leavey S F, Cibrik D M, Arndorfer J A, Leichtman A B, Punch J D, Armstrong D R, Kaplan B. Differences in etiology for graft loss in female renal transplant recipients. TRANSPLANT PROC, 33: 12881290 (2001) Meier Kriesche H U, Ojo A O, Leavey S F, Hanson J A, Leichtman A B, Magee J C, Cibrik D M, Kaplan B. Gender differences in the risk for chronic renal allograft failure. TRANSPLANTATION, 71: 429-432 (2001) Antus B, Yao Y S, Song E W, Liu S Y, Lutz J, Heemann U. Opposite effects of testosterone and estrogens on chronic allograft nephropathy. TRANSPLANT INT, 15: 494-501 (2002) Contreras J L, Smyth C A, Bilbao G, Young C J, Thompson J A, Eckhoff D E. 17 beta-estradiol protects isolated human pancreatic islets against proinflammatory cytokine-induced cell death: Molecular mechanisms and islet functionality. TRANSPLANTATION, 74: 1252-1259 (2002) Dubey R K, Oparil S, Imthurn B, Jackson E K. Sex hormones and hypertension. CARDIOVASC RES, 53: 688-708 (2002) Inoue S, Yamada Y, Kuzuhara K, Ubara Y, Hara S, Ootubo O. Are women privileged organ recipients? TRANSPLANT PROC, 34: 2775-2776 (2002) Kang A K, Miller J A. Effects of gender on the renin-angiotensin system, blood pressure, and renal function. CURR HYPERTENS REP, 4: 143-151 (2002) Lane P H. Diabetic kidney disease: impact of puberty. AMER J PHYSIOL-RENAL PHYSIOL, 283: F589-F600 (2002) Meier Kriesche H U, Cibrik D M, Ojo A O, Hanson J A, Magee J C, Rudich S M, Leichtman A B, Kaplan B. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J AMER GERIAT SOC, 50: 14-17 (2002) Muller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabo A J. Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin. KIDNEY INT, 62: 1364-1371 (2002) Schmidt A, Luger A, Horl W H. Sexual hormone abnormalities in male patients with renal failure. NEPHROL DIALYSIS TRANSPLANT, 17: 368-371 (2002) Song E W, Zou H Q, Yao Y S, Proudfoot A, Antus B, Liu S Y, Jens L, Heemann U. Early application of Met-RANTES ameliorates chronic allograft nephropathy. KIDNEY INT, 61: 676-685 (2002) Antus B, Hamar P, Kokeny G, Szollosi Z, Mucsi I, Nemes Z, Rosivall L. Estradiol is nephroprotective in the rat remnant kidney. NEPHROL DIALYSIS TRANSPLANT, 18: 54-61 (2003) Kang A K, Miller J A. Impact of gender on renal disease: the role of the renin angiotensin system. CLIN INVEST MED, 26: 38-44 (2003) Kayler U K, Rasmussen C S, Dykstra D M, Ojo A O, Port F K, Wolfe R A, Merion R M. Gender imbalance and outcomes in living donor renal transplantation in the United States. AM J TRANSPLANT, 3: 452-458 (2003) Silbiger S R, Neugarten J. The role of gender in the progression of renal disease. ADV RENAL REPLACE THER, 10: 3-14 (2003) Marshall M B, Kohman L J. Gender and lung transplantation: Size matters, does sex? J THORAC CARDIOVASC SURG, 128: 352-353 (2004) Muller V, Szabo A. Gender associated differences in the progression of renal diseases. LEGE ARTIS MEDICINAE, 14: (1) 26-31 (2004) Smith M C, Ward M K, Sturgiss S N, Milne J E, Davison J M. Sex and the pregnant kidney: Does renal allograft gender influence gestational renal adaptation in renal transplant recipients? TRANSPLANT PROC, 36: 2639-2642 (2004) Wang M H, Liu S Y, Ouyang N, Song E W, Lutz J, Heemann U. Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration. KIDNEY INT, 66: 1248-1256 (2004) Antus B, Liu S Y, Yao Y S, Zou H Q, Song E W, Lutz J, Heemann U. Effects of progesterone and selective oestrogen receptor modulators on chronic allograft nephropathy in rats. NEPHROL DIALYSIS TRANSPLANT, 20: 329-335 (2005) Gu Y L, Dirsch O, Dahmen U, Ji Y, He Q, Chi H D, Broelsch C E. Impact of donor gender on male rat recipients of small-for-size liver grafts. LIVER TRANSPLANT, 11: 669-678 (2005) Lane P H. Puberty and chronic kidney disease. ADV CHRONIC KIDNEY DIS, 12: 372-377 (2005) Reyes D, Lew S Q, Kimmel P L. Gender differences in hypertension and kidney disease. MED CLIN N AMER, 89: 613(2005) Rusai Krisztina, Reusz György. A nitrogén-monoxid-rendszer szerepe a vese ischemia-reperfúziós károsodásában /The role of nitric oxide in the pathogenesis of renal ischemia-reperfusion injury/. HYPERTONIA ÉS NEPHROLOGIA, 9 (34): 150-156 (2005) Sun J H, Langer W J, Devish K, Lane P H. Compensatory kidney growth in estrogen receptor-alpha null mice. AMER J

PHYSIOL-RENAL PHYSIOL, 290: F319-F323 (2006) Lekgabe ED, Royce SG, Hewitson TD, et al. The effects of relaxin and estrogen deficiency on collagen deposition and 33. hypertrophy of nonreproductive organs. ENDOCRINOLOGY, 147 (12): 5575-5583(2006) Lu H, Lei X, Klaassen C. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 34. nephrectomized rats. KIDNEY INTERNATIONAL, 70 (11): 1920-1928 (2006) Antus B, Fillinger J, Sebe A, Jeney C, Soltesz I, Horvath I. No gender difference in development of obliterative 35. airway disease in rat tracheal allografts. EXPERIMENTAL AND MOLECULAR PATHOLOGY 81 (3): 235-238 (2006)

88. Hamar P, Szabó A, Kovács G, Kökény G, Heemann U, Rosiwall L. Az interleukin-2 által közvetített mechanizmusok szerepet játszanak transplantált patkányvese chronicus kilökődésében. Hypertonia és Nephrologia 1999; 3(2): 102-109 89. Hamar P, Szabo A, Muller V, Heemann U. Involvement of interleukin-2 and growth factors in chronic kidney allograft rejection in rats. Transplant P 2001; 33: 2160-2162 IF: 0,568 Független idézettség: 1 1.

Joosten S A, van Kooten C, Paul L C. Pathogenesis of chronic allograft rejection. TRANSPLANT INT, 16: 137-145 (2003)


Nem a disszertáció témájában a PhD értekezést megelőzően megjelent társszerzős közlemények

90. Ross RS, Viazov S, Schmitt U, Schmolke S, Tacke M, Ofenloch-Haehnle B, Holtman M, Müller N, Da Villa G, Yoshida CF, Oliveira JM, Szabo A, Paladi N, Kruppebacher JP, Philipp Th, Roggendorf M. Distinct prevalence of antibodies to the E2 protein of GB virus C/hepatitis G virus in different parts of the world. J Med Virol 1998; 54: 103-106 IF: 2,594 Független idézettség: 36 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.

Birkenmeyer L G, Desai S M, Muerhoff A S, Leary T P, Simons J N, Montes C C, Mushahwar I K. Isolation of a GB virus-related genome from a chimpanzee. J MED VIROL, 56: 44-51 (1998) Mphahlele M J, Lau G K K, Carman W F. HGV: the identification, biology and prevalence of an orphan virus. LIVER, 18: 143-155 (1998) Brojer E, Grabarczyk P, Kryczka W, Kucharski W, Kubicka J, Zupanska B. Analysis of hepatitis G virus infection markers in blood donors and patients with hepatitis. J VIRAL HEPATITIS, 6: 471-475 (1999) Cabrerizo M, Bartolome J, de Sequera P, Caramelo C, Manzano M L, Carreno V. GBV-C/HGV-RNA in serum and peripheral blood mononuclear cells in hemodialysis patients. KIDNEY INT, 56: 1120-1128 (1999) Cesaire R, Martial J, Maier H, Kerob Bauchet B, Bera O, Duchaud E, Brebion A, Pierre Louis S. Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean island. J MED VIROL, 59: 160-163 (1999) Fogeda M, Navas S, Martin J, Casqueiro M, Rodriguez E, Arocena C, Carreno V. In vitro infection of human peripheral blood mononuclear cells by GB virus C hepatitis G virus. J VIROL, 73: 4052-4061 (1999) Goubau P, Andrade F B, Liu H F, Basilio F P D, Croonen L, Barreto Gomes V A F. Prevalence of GB virus C hepatitis G virus among blood donors in north-eastern Brazil. TROP MED INT HEALTH, 4: 365-367 (1999) Heinsen A, Fomsgaard A. Hepatitis G virus or GB virus C; [hepatitis G-virus eller GB virus-C]. UGESKR LAEGER, 161: (18) 2653-2656 (1999) Hwang S J, Lu R H, Chan C Y, Chang F Y, Lee S D. Detection of antibodies to E2-protein of GB virus-C hepatitis G virus in patients with acute posttransfusion hepatitis. J MED VIROL, 57: 85-89 (1999) Liu C J, Kao J H, Lai M Y, Chen P J, Chu J S, Chen W, Chen D S. Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. J GASTROENTEROL HEPATOL, 14: 352-357 (1999) Lodi G, Carrassi A, Scully C, Porter S R. Hepatitis G virus: Relevance to oral health care. ORAL SURG ORAL MED ORAL PATHO, 88: 568-572 (1999) Rey D, Fraize S, Vidinic J, Meyer P, Fritsch S, Labouret N, Schmitt C, Lang J M, Stoll Keller F. High prevalence of GB virus C hepatitis G virus RNA in patients infected with human immunodeficiency virus. J MED VIROL, 57: 75-79 (1999) Sathar M A, Soni P N, Naicker S, Conradie J, Lockhat F, Gouws E. GB virus C/hepatitis G virus infection in KwaZulu Natal, South Africa. J MED VIROL, 59: 38-44 (1999) Wong S B J, Chan S H, Ren E E C. Diversity of GB virus C hepatitis G virus isolates in Singapore: Predominance of group 2a and the Asian group 3 variant. J MED VIROL, 58: 145-153 (1999)

15. 16. 17. 18. 19.

20.

21.

22. 23. 24. 25. 26. 27.

28. 29. 30. 31. 32. 33.

34. 35. 36.

Anastassopoulou C G, Paraskevis D, Tassopoulos N C, Boletis J, Sypsa V A, Hess G, Hatzakis A. Molecular epidemiology of GB virus C/hepatitis G virus in Athens, Greece. J MED VIROL, 61: 319-325 (2000) Fabrizi F, Lunghi G, Pozzi C, Colzani S, Tentori F, Del Vecchio L, Corti M, Pagano A, Locatelli F. GBV-C/HGV infection in end-stage renal disease: a serological and virological survey. J NEPHROLOGY, 13: 68-74 (2000) Giulivi A, Slinger R, Tepper M, Sher G, Scalia V, Kessler G, Gill P. Prevalence of GBV-C/hepatitis G virus viremia and anti-E2 in Canadian blood donors. VOX SANG, 79: 201-205 (2000) Guardia J. Hepatitis G virus. A lot of noise, but... MED CLIN, 114: 735-736 (2000) Hwang S J, Chu C W, Lu R H, Lan K H, Wu J C, Wang Y J, Chang F Y, Lee S D. Seroprevalence of GB virus C hepatitis G virus-RNA and anti-envelope antibody in high-risk populations in Taiwan. J GASTROENTEROL HEPATOL, 15: 1171-1175 (2000) Picerno I, Calisto ML, Spataro P, Ventura E, Di Pietro A, Scoglio ME. Anti HGV seroprevalence related to HCV infection; [prevalenza di anticorpi anti epatite G (HGV) e relazione con l'infezione da HCV]. Igiene Moderna, 114: (3) 197-204 (2000) Rey D, Vidinic Moularde J, Meyer P, Schmitt C, Fritsch S, Lang J M, Stoll Keller F. High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. EUR J CLIN MICROBIOL INFECT D, 19: 721-724 (2000) Yu M L, Chuang W L, Wang L Y, Dai C Y, Chiou S S, Sung M H, Chang C S, Chen S C, Wang C S, Chang T T, Chang W Y. Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. J GASTROENTEROL HEPATOL, 15: 1404-1410 (2000) Halasz R, Weiland O, Sallberg M. GB virus C/hepatitis G virus. SCAND J INFEC DIS, 33: 572-580 (2001) Kleinman S. Hepatitis G virus biology, epidemiology, and clinical manifestations: Implications for blood safety. TRANSFUS MED REV, 15: 201-212 (2001) Tucker TJ, Smuts HE. Review of the epidemiology; molecular characterization and tropism of the hepatitis G virus/GBV-C. Clinical Laboratory, 47: 239-248 (2001) Villari P, Ribera G, Nobile C G A, Torre I, Ricciardi G. Antibodies to the E2 protein of GB virus C hepatitis G virus: Prevalence and risk factors in different populations in Italy. INFECTION, 29: 17-23 (2001) Yu M L, Chuang W L, Dai C Y, Lu S N, Wang J H, Huang J F, Chen S C, Lin Z Y, Hsieh M Y, Tsai J F, Wang L Y, Chang W Y. The serological and molecular epidemiology of GB virus C/hepatitis G virus infection in a hepatitis C and B endemic area. J INFECTION, 42: 61-66 (2001) Anastassopoulou C G, Delladetsima J K, Anagnostopoulos G, Katsoulidou A, Papachristopoulos A, Tassopoulos N C, Theodoridou M, Hatzakis A. Fulminant hepatic failure in a pediatric patient with active GB virus C (GBV-C)/hepatitis G virus (HGV) infection. HEPATOL RES, 23: 85-89 (2002) Chow WC, Lee ASG, Seo YC, Tan CK, Ng HS. Prevalence of hepatitis G virus infection in patients with liver diseases in singapore. Singapore Medical Journal, 43: (2) 67-69 (2002) Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch U R, Schmidt W E. Prevalence of and risk factors for hepatitis G (HGV) infection in haemodialysis patients: a multicentre study. NEPHROL DIALYSIS TRANSPLANT, 17: 271-275 (2002) Saitoh H, Moriyama M, Matsumura H, Goto I, Tanaka N, Aarakawa Y. The clinical significance of GBV-C/HGV exposure in C-viral chronic liver disease and blood donors. HEPATOL RES, 22: 288-296 (2002) Takacs M, Szomor K N, Szendroi A, Dencs A, Brojnas J, Rusvai E, Berencsi G. Prevalence of GB virus C/hepatitis G virus in Hungary. FEMS IMMUNOL MED MICROBIOL, 34: 283-287 (2002) Christensen P B, Fisker N, Mygind L H, Krarup H B, Wedderkopp N, Varming K, Georgsen J. GB virus C epidemiology in Denmark: Different routes of transmission in children and low- and high-risk adults. J MED VIROL, 70: 156-162 (2003) Nishiya AS, Ribeiro-Dos-Santos G, Bassit L, Focaccia R, Chamone DF, Sabino EC. Genotype distribution of the GB virus C in citizens of Sao paulo city; brazil. REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO., 45: (4) 213-216 (2003) Roy K M, Bagg J, Kennedy C, Cameron S, Simmonds P, Lycett C, Hunter I, Taylor M. Prevalence of GBV-C infection among dental personnel. J MED VIROL, 70: 150-155 (2003) Abu Odeh R O, Al Moslih M I, Al Jokhdar M W, Ezzeddine S A. Detection and genotyping of GBV-C virus in the united Arab emirates. J MED VIROL, 76: 534-540 (2005)

91. Reusz György, Sallay Péter, Dobos Mariann, Szabó András, Szabó Attila, Szabó Antal, Tulassay Tivadar. Az oxalátürítés és a vizelet kalcium-oxalát telítettsége izolált haematuriában valamint idiopathiás hypercalciuriában. Gyermekgyógyászat 1998; 6: 560-567

92. Szabó A, Kenesei É, Szabó A, Arató A, Reusz Gy, Tulassay T. Bone turnover index in children and their changes in renal diseases. Klin Kisérl Lab Med = Clin Exp Lab Med 2000; 27: 66-71 (angol nyelvű) Össz impakt faktor: 2,594 Független idézettség: 36

Impakt faktor összesítés és százalékos arány a küszöbértékhez viszonyítva Az első- vagy utolsószerzős publikációk impakt faktora: 37,549 (75,098%) Az első- vagy utolsószerzős publikációk független idézettsége: 138 (69%) A PhD Disszertációt követően és megelőzően publikált első- vagy utolsószerzős közlemények impakt faktorának aránya: 32,099/5,450 (85,48%/14,52%) A PhD Disszertációt követően és megelőzően publikált első- vagy utolsószerzős közlemények független idézettségének aránya: 86/52 (62,3%/37,7%) A PhD Disszertációt követően és megelőzően publikált összes közlemény impakt faktorának aránya: 75,488/16,081 (82,44%/17,56%) Összes impakt faktor: 91,569 Független idézettség: 350 Összes idézettség: 422

KÖZLEMÉNYJEGYZÉK (Szabó Attila)

Recommend Documents